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Abstract 
Galectins are a group of β-galactoside-binding proteins involved in different cellular 
processes including stress responses and differentiation. The role and expression of 
galectins under oxidative stress and during neutrophilic differentiation was examined in 
HL-60 cells. Galectin gene (LGALS), and galectin protein expression were determined 
using RT-qPCR and immunoblotting, respectively. Neutrophilic differentiation was 
measured via a spectrofluorometric assay. DNA methylation and JNK signaling were 
investigated as galectin regulatory mechanisms. Menadione-induced oxidative stress, 
DMSO-induced differentiation, DNA hypomethylation and JNK signaling all promoted 
similar galectin expression profiles. Antioxidant N-acetylcysteine attenuated the 
menadione-induced galectin expression but only partially attenuated DMSO-induced 
galectin expression. Galectin inhibitory sugars decreased cell proliferation and inhibited 
differentiation. Finally, correlative analysis suggests galectins are biomarkers of oxidative 
stress and cellular differentiation. My findings indicate that galectins represent novel 
therapeutic targets in the context of acute myeloid leukemia and their expression profiles 
can be considered biomarkers of oxidative cell stress and differentiation. 
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Chapter 1  
1 Introduction 
1.1 Galectins – an overview 
Galectins are a family of glycan-binding proteins with binding specificity toward β-
galactosides (Barondes et al., 1994). Originally, discovered in 1975 by Teichberg et al. the 
first vertebrate galectin from Electrophorus electricus (eel) was originally named 
“electrolectin”, and was found to be inhibited by β-ᴅ-galactosyl residues while having 
lectin like activity within mammalian cell culture (Teichberg et al., 1975). Shortly 
thereafter other research groups started purifying related lectins from other vertebrate 
tissues. Galectin-1 was purified in 1976 from calf heart and lung (de Waard et al., 1976), 
and the first avian galectin from chicken muscles (Nowak et al., 1976). Some years later 
galectin-3 was identified in fibroblasts (Roff and Wang, 1983), and then purified a year 
later from mouse lung (Crittenden et al., 1984). Galectins are relatively small in size and 
have specific binding toward N-acetyllactosamine-enriched glycoconjugates. They are part 
of a larger family of proteins known as lectins that are found more predominately in plants 
and exhibit high specificity toward many different sugar moieties (Varki et al., 2009). Since 
their original discovery galectins have undergone various name changes including: 
galaptin, S-Lac and S-type lectins before finally being designated as “galectin” in 1994 to 
avoid name discrepancies (Allen et al., 1990; Barondes et al., 1994; Thiemann and Baum, 
2016). Today, 16 galectin genes have been identified in mammals with 12 galectins being 
characterized and sequenced in humans (Thiemann and Baum, 2016; Timoshenko, 2015) 
however, these proteins have been identified across all eukaryotic taxa. Others, for 
example, galectin-5 and -6 are found in rodents, while galectin-11 has been identified in 
sheep, but is not found in humans (Varki et al., 2009). Galectin activity has been well 
reported across many tissues and their differential regulation is important for maintaining 
cellular functions (Laderach et al., 2013). Since their original discovery, galectins have 
been identified in both vertebrates and invertebrates including: mammals, amphibians, fish, 
birds, reptiles, nematodes, sponges and even fungi (Gupta, 2012). 
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Galectins may be secreted into the extracellular matrix where they will bind their 
appropriate glycoreceptor at the cell surface; initiating a signal transduction pathway, 
which drives gene expression of factors important for various biological functions. 
Specifically, galectins serve as mediators of several fundamental biological processes 
including: cell growth (Manzi et al., 2016), apoptosis (Stillman et al., 2006), immune 
function (Chung et al., 2013), differentiation (Abedin et al., 2003), migration and adhesion 
(Perillo et al., 1998). Although all galectins display affinity toward lactose – N-
acetyllactosamine and poly-N-acetyllactosamine residues are located on different 
glycoconjugates and modification of these sugar moieties can define galectin specific 
binding/functionality (Ahmad et al., 2004). Even though galactose is the basic recognition 
element for many galectins; actual glycans present on different proteins/lipids at the cell 
surface are more complicated in vivo. Galectins typically exist as dimers (also multimers) 
allowing a single galectin to bind multiple sites. Lectin-carbohydrate interactions are 
relatively weak; therefore, structural orientation of the peptide sequence of the galectin can 
allow for multiple galectin binding domains to bind their respective ligand at the same time, 
creating a stronger interaction and lowering the dissociation constant. For example, 
generally, galectins bind glycoreceptors containing N-acetyllactosamine residues with a 
dissociation constant (Kd) of 90 – 100 µM but galectins can also bind glycoreceptors 
containing polylactosamine sequences with stronger affinity: Kd value of 1 µM 
(Rabinovich et al., 2002). In a biological context, galectins do not bind the simple 
disaccharides alone but rather lactosamine sequences that are present on complex N-
glycans and O-glycans on numerous branches leading to high-avidity binding since the 
affinity of each galectin binding site for its respective ligand is additive in a multimeric 
complex (Thiemann and Baum, 2016). Therefore, it is important to understand the 
structural differences of galectins to better define their roles in different tissues and explain 
why certain galectins are only expressed within specific tissues while others are not. 
1.2 Structural features and classification 
Galectins are grouped according to their structural domain composition (Hirabayashi and 
Kasai, 1993). Specifically, all galectins are characterized, identified and often classified 
according to their respective carbohydrate recognition domain(s) (CRD). The CRD 
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consists of about 135 amino acids, composing two protein β-sheets, which are formed by 
five and six β-strands each folded antiparallel to each other forming a pocket for the 
respective glycan to bind (Cooper, 2002; Thiemann and Baum, 2016). All galectins contain 
either one or multiple CRDs, distinguishing homo-dimeric from hetero-dimeric galectins. 
Galectins were once originally referred to as S-type lectins; this was to denote that many 
galectins contained free cysteine residues (Varki et al., 2009). In fact, it has been stated 
that certain galectins required the inclusion of β-mercaptoethanol in buffers to maintain 
their activity, perhaps because of the disulfide linkage of cysteine residues – important for 
proteins structure (Varki et al., 2009). More recent studies have shown that, mouse 
galectin-2 for example, only require a certain cysteine (Cys75) residue present in the amino 
acid motif of the CRD for this domain to exhibit lectin-binding capabilities while 
mutagenesis of other conserved free cysteine residues had no effect (Tamura et al., 2016). 
Galectin-1 for example, contains six cysteine residues (Cys2-Cys16, Cys42-Cys60, Cys88-
Cys130), which are required to be in a reduced state to allow for proper carbohydrate 
binding activity and biological function (Kadoya and Horie, 2005; Klyosov, 2008). 
However, other studies have shown that site-directed mutagenesis of these cysteine 
residues into serine residues did not inhibit sugar binding (Liao et al., 1994) but that 
mutagenesis of other conserved hydrophilic residues abolished carbohydrate binding 
activity (Hirabayashi and Kasai, 1991). Interestingly, the amino acid sequences of the CRD 
are highly homologous across and within species (90% of the 134 amino acids are identical 
between humans and mice) (Kadoya and Horie, 2005). The structural features and 
organization of the CRD categorize galectins into the following 3 sub-families: proto-type, 
tandem-repeat and chimeric galectins. 
Despite the CRD playing a dominant role in galectin function; other non-lectin domains 
also play functional roles. In fact, non-lectin domains of galectins are often crucial for 
specific protein-protein interactions – despite being less frequent than CRD-dependent 
interactions. Park et al. (2001) demonstrate that galectin-1 and -3 are factors required for 
pre-mRNA splicing within HeLa cells through a non CRD-dependent interaction (Park et 
al., 2001). Additionally, intracellular galectin-1 has been reported to interact with H-Ras, 
a gene frequently mutated in tumours to promote malignant differentiation, in multiple cell 
lines including HeLa, HEK293, Rat1 and Molt4 in a CRD-independent fashion (Camby et 
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al., 2006; Yu et al., 2015). Interestingly, Liu et al. (1996) used murine monoclonal 
antibodies to bind epitopes along the amino-terminal region of galectin-3, which inhibited 
galectin-mediated superoxide production (Liu et al., 1996). In fact, most galectins have 
features typical of cytoplasmic proteins including an acetylated N-terminus, free thiol 
groups and absence of glycosylation, which inherently affects their localization and 
functional capacity. 
Galectin localization is important for determining their function. These proteins can work 
both intracellularly by interacting with various intracellular ligands or extracellularly by 
mediating cell-cell, cell-matrix interactions and by binding cell surface glycans to activate 
a signal transduction pathway (Gupta, 2012; Varki et al., 2009). Galectin-1 shows multiple 
functions depending on its subcellular localization. Intracellularly, galectin-1 can arrest cell 
growth while extracellular galectin-1 can induce proliferation or apoptosis (Stillman et al., 
2005). Contrasting roles in galectin-1 localization function are likely due to CRD-
dependent interactions happening exclusively in the extracellular matrix. Interestingly, 
however, galectins lack any signal sequence for classical secretion into the extracellular 
space despite the regulation of galectin secretion being markedly changed during different 
cellular processes (Hirabayashi and Kasai, 1993; Sato and Hughes, 1994). Additionally, 
structural characteristics of galectins including an acetylated N-terminus, absence of both 
disulfide bonds and glycan chains indicate that these proteins would normally reside within 
the cytoplasm despite being biologically active in the extracellular space and on the cell 
surface. It is surprising that galectins are secreted at all considering the oxidizing 
environment of the extracellular space (which would affect galectin folding). Therefore, 
the biological function of galectins in the oxidative extracellular space may be dependent 
on their immediate binding to glycoreceptors, which would prevent oxidation of free 
cysteine residues (Vasta, 2009). It has been proposed that galectins may exit cells according 
to the structure of the protein, the cell type and its polarity (Hughes 1999). Interestingly, 
different cell types secrete different levels of total produced galectin. CHO-K1 cells have 
been reported to secrete all expressed galectin-3 (Sato et al., 1993) while BHK-21 cells 
secrete only 12% (Lindstedt et al., 1993). Identification of secreted galectins and their 
localization within different tissues is clinically important especially when designing drugs 
that bind galectins as therapeutic targets particularly those that are overexpressed in 
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different cancers. Despite the accumulation of data on individual galectins, there is still no 
galectin “signature/profile” that identifies their function across cell types (Laderach et al., 
2013). This is, in part, due to galectins displaying multifaceted biological functions. For 
example, galectin-3 has been reported to display both anti-apoptotic and pro-apoptotic 
effects (Fukumori et al., 2003; Nakahara et al., 2005). Often many differences in galectin 
expression can be seen across various cancer lines (Satelli et al., 2008), and even altered 
galectin transcript levels, which are dependent on specific cellular differentiation events 
(Abedin et al., 2003). 
Prototypical galectins 
The galectins in this family are galectin-1, -2, -5, -7, -10, -11, -13, -14, -15 and -16. 
Prototypical galectins are generally smaller (14-16 kDa) than others and have a single 
galactoside binding domain with a short peptide region followed by an N-terminal 
sequence. These proteins can exist either as a galectin monomer or more typically as a 
homodimer. There are 8 conserved amino acids in the CRD that allow for proper binding 
of prototypical galectins (Hirabayashi and Kasai, 1991; Lobsanov et al., 1993). Monomeric 
galectins consist of galectin-5, -10 and -14 while galectins-1, -2, -7, -11, -13, -15 and -16 
exist as non-covalent homodimers.  
Tandem-repeat galectins 
Galectin-4, -6, -8, -9 and -12 fall under this subfamily and are generally larger (between 
35-39 kDa) than other galectins. These galectins contain two non-identical CRDs: one 
being located at the N-terminus with the other at the C-terminus, linked together by a short 
linker peptide region that is roughly 25 – 35 amino acids in size – highly rich in proline 
and glycine residues. There is evidence that this linker region increases susceptibility of 
these proteins to proteolysis and that truncated versions increase resistance toward 
degradation (Nishi et al., 2005). As a result, these galectins are typically less stable than 
the others. 
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Chimeric galectins 
Currently, galectin-3 is the only galectin classified as a chimeric type and it is 26 kDa in 
size. This monomeric galectin contains two functional domains: the N-terminal regulatory 
domain and the C-terminal CRD. The N-terminal regulatory domain contains many 
repeated collagen-like sequences (7-14 regions with 8-11 amino acids in each) (Rapoport 
et al., 2008; Weis and Drickamer, 1994), and shares high homology with the heterogeneous 
nuclear ribonucleoprotein complex (Jia and Wang, 1988). The regulatory domain of 
galectin-3 is also phosphorylated on at least two different residues and is susceptible to 
cleavage by enzymes that impact its ability for both lectin binding and self-oligomerization 
(Balan et al., 2012; Rapoport et al., 2008). Oligomerization is a unique trait of galectin-3, 
which allows this protein to form galectin-glycan structures between and across cell 
surfaces. 
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Figure 1. Classification of galectins based on their molecular structure. Galectins are 
classified based on their carbohydrate recognition domains (black and grey), non-
lectin linker domain (blue and light blue) and N-terminal end domains (brown). 
Illustration above shows the basic molecular characteristics of human galectins (adapted 
from Timoshenko et al. [2016]). Prototype galectins may form homodimers (not shown). 
Tandem-repeat galectins contain two non-identical CRDs joined together by a short linker 
peptide region. Chimeric galectin-3 is monomeric, however, may oligomerize using its N-
terminal end domain (brown circle) to form pentamers. 
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1.3 Cellular functions of galectins 
Numerous studies have shown that galectins play prominent roles in cell signaling, 
crosslinking and interactions with a variety of ECM molecules. This is achieved by 
galectins through their ability to interact with glycolipids (Ahmed et al., 2002), 
glycoprotein receptors (Stillman et al., 2006), integrins (Friedrichs et al., 2008) and other 
ligands to mediate cellular functions (Boscher et al., 2011). Further, galectins often regulate 
other molecular targets to facilitate these biological functions. For example, exposure 
treatment of galectin-1, -2, -3, -4 and -7 promotes adhesion of human breast cancer cells 
accompanied by increased production of the lymphangiogenic factor: vascular endothelial 
growth factor-C (VEGF-C) (Timoshenko et al., 2010). Further, galectins induce a variety 
of functional cellular responses such as aggregation of blood and immune cells, activation 
of neutrophils (production of ROS and degranulation), and an increase in cytoplasmic Ca2+ 
availability (Timoshenko et al., 1995, 1997, 2003). Each galectin has slightly different 
affinity toward galactose, dependent on glycan structural organization on the cell surface 
with other complex oligosaccharides. Moreover, structural differences between galectins 
allow each galectin to maintain a certain role within different tissues despite significant 
homology. 
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Figure 2. Interactions between cell surface glycoconjugates (black cylinders represent 
transmembrane receptors, orange circles and squares represent galactose-containing 
oligosaccharides) with various galectin family members (green proto, blue chimeric, 
yellow tandem-repeat) which facilitates cellular functions.  
The illustration above demonstrates the facilitation of galectin binding which can mediate 
signal transduction and cell adhesion events, among others (adapted from Liu and 
Rabinovich [2005]). 
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1.3.1 Galectin-1 
Generally, galectin-1 is differentially expressed by both tumourigenic and normal tissues, 
mediating of a wide variety of biological functions that are dependent on protein-
carbohydrate and protein-protein interactions (Camby et al., 2006). Galectin-1 is typically 
associated with initiating and augmenting inflammatory responses including apoptosis, 
adhesion and migration. This galectin is capable of inducing cell death of both resting 
(Perillo et al., 1995), and activated (Matarrese et al., 2005) T-cells. Similarly, upregulation 
of galectin-1 expression promotes apoptosis in rat macrophages and activated T-cells, 
suppress in vitro T-cell activation and inhibits cellular proliferation (Blaser et al., 1998; 
Rabinovich et al., 1998). Cells overexpressing galectin-1 are able to increase cell migration 
by binding, in a CRD-dependent manner, to fibronectin, laminin and collagen (Horiguchi 
et al., 2003) through cross-linking glycoproteins exposed on the cell surface. Interestingly, 
galectin-1 can differentially impact the effect of cell proliferation depending on cell type. 
For example, galectin-1 has been shown to inhibit proliferation in lymphocytes, 
neuroblastoma and prostate cancer while increasing cell proliferation in cervical, ovarian 
and pancreatic tumour cells (Vladoiu et al., 2014). More interestingly, galectin-1 has been 
shown to elicit contrasting effects on the same cell type. Yamaoka et al. (2000) 
demonstrated that inhibition of the galectin-1 gene (LGALS1) decreases rat brain tumour 
cell proliferation while Kopitz et al. (2001) showed that administration of recombinant 
galectin-1 inhibited brain tumour growth (Kopitz et al., 2001; Yamaoka et al., 2000). 
Most evidence, however, suggests galectin-1 as a master regulator of various immune 
responses including T-cell survival and immune disorders, inflammation and allergies 
(Gupta, 2012) achieved by binding of various glycoconjugate receptors (CD45, CD32 and 
CD7) (Pace et al., 1999). Most interestingly, it has been shown that secreted galectin-1 is 
able to promote tumour cell evasion of the immune response; likely mediated by binding 
CD4 and CD8 receptors of immune T-cells to promote apoptosis (Rubinstein et al., 2004), 
an effect that can be attenuated by the addition of lactose. Typically this galectin works in 
an anti-inflammatory manner by suppressing the secretion of the pro-inflammatory 
cytokine interleukin-2 (IL-2) (Rabinovich et al., 1999), and promoting the release of anti-
inflammatory cytokine interleukin-10 (IL-10) (van der Leij et al., 2004). Kiss et al. (2007) 
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provide evidence of reduced swelling through edema assay testing providing more 
evidence of an anti-inflammatory role for this galectin (Kiss et al., 2007). Today, many CD 
receptors have been recognized as galectin-1 binding partners (Elola et al., 2005), however, 
it has been shown that different galectins have a specific preference for separate 
glycoprotein CD receptors despite high CRD homology (Stillman et al., 2006). 
1.3.2 Galectin-3 
There is a considerable amount of literature on galectin-3 highlighting its biological 
activity, which is strongly influenced by its localization, cell type, neoplastic processes, 
cellular proliferation status and others (Dumic et al., 2006). The localization of galectin-3 
can strongly affect its biological activity. Generally, intracellular galectin-3 acts as an anti-
apoptotic factor while extracellular galectin-3 is pro-apoptotic (Dumic et al., 2006). 
Galectin-3 has been shown to work intracellularly with multiple different ligands in the 
cytoplasm including Bcl-2 (Akahani et al., 1997; Yang et al., 1996), APO-1/Fas (Fukumori 
et al., 2004), Nucling (Liu et al., 2004), and AIPI (Liu et al., 2002) to mediate apoptotic 
events (either pro- or anti-apoptotic).  
Galectin-3 is able to work in the nucleus to mediate gene transcription that affects cell 
proliferation (Paron et al., 2003), and cell cycle regulation (Kim et al., 1999). Similar to 
the only documented function of nuclear galectin-1; galectin-3 is also capable of binding 
Gemin-4 subsequently affecting post-transcriptional regulation of mRNA processing 
(Paushkin et al., 2002).  
Extracellular galectin-3 is able to mediate cell-ECM interaction through binding to laminin, 
fibronectin, elastin, collagen IV and mediate cell-cell interactions through preferential 
binding to the ligand N-acetyllactosamine located on CD receptors and glycoreceptors 
(Dumic et al., 2006). In this way, galectin-3 regulates cell adhesion and migration primarily 
through interaction with integrins in a CRD-dependent manner (Ochieng et al., 1998).  
Similar to galectin-1, galectin-3 is also predominately involved in immune function. 
Galectin-3 can bind CD receptors to suppress apoptosis or increase proliferation (Akahani 
et al., 1997; Yang et al., 1996). It has been proposed that the role of galectin-3 is to 
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oligomerize with itself and then bridge monocyte activated macrophages to apoptotic 
neutrophils in order to increase their uptake (Karlsson et al., 2009) suggesting that the 
structural characteristics (divalent vs multivalent), and glycan specificity (receptor 
selectivity) provide contrasting roles for similar galectins. 
The maintenance of endogenous galectins is crucial in their ability to carry out biological 
roles. For example, phosphorylation of the regulatory domain of galectin-3 is critical for 
protecting it from subsequent cleavage by the prostate specific antigen (Balan et al., 2012). 
This provides evidence of the phosphorylated/non-phosphorylated galectin-3 ratio as a 
prognostic marker of prostate cancer considering intact galectin-3 increases levels of 
angiogenesis and metastasis. Galectin-3 may also be used as a marker of cellular stress 
responses considering many tumourigenic processes are involved with different types of 
cell stress. 
Additionally, galectin-3 expression is vastly upregulated near sites of inflammation. 
Galectin-3 is typically described as a pro-inflammatory galectin, in contrast to galectin-1. 
Galectin-3 can potentiate inflammatory responses by increasing superoxide anion 
production, increase adhesion of neutrophils to components of the ECM and work in a 
similar fashion to that of cytokines to affect both innate and adaptive immunity. Another 
interesting quality of this galectin during immune response is that it is able to recognize 
glycoreceptors present on foreign pathogens (Mandrell et al., 1994). Although the specific 
function for galectin-3 binding foreign pathogens is not well understood, galectin-3 
knockout murine models display a reduced ability to clear infection (Beatty et al., 2002), 
and develop fewer white blood cells than wild type mice (Zuberi et al., 2004). 
1.3.3 Galectins-8, -9, -10 and -12 
Galectin-8 is a tandem-repeat galectin that effects a wide variety of functions including cell 
adhesion, cell proliferation, apoptosis and others (Tribulatti et al., 2007; Zick et al., 2004). 
Interestingly, this galectin has also elicited opposing roles dependent on cell type. For 
example, galectin-8 has been shown to induce apoptosis in thymocytes (Tribulatti et al., 
2007) while preventing apoptosis in brain cancer (Metz et al., 2016). This galectin is well 
characterized in cancer and its expression levels correlate with the degree of malignancy 
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and differentiation of different tumours (Bidon-Wagner and Le Pennec, 2004). In fact, a 
galectin finger-printing study revealed that galectin-8 was detected in all but two of 61 
different human tumour cell lines and was more highly expressed than galectins-1, -2, -3, 
-4, -7 and -9 (Lahm et al., 2001). 
Galectin-9 is also a tandem-repeat galectin classically known to be a regulator of both 
adaptive and innate immunity and functions by inducing secretion of a variety of cytokines 
from different blood cells (Kojima et al., 2014; Matsuura et al., 2009). Recently, increased 
galectin-9 expression has been suggested as a marker of distinct cancer types where other 
galectins are notably downregulated (Muniz et al., 2015). 
Galectin-10, also known as Charcot-Leyden crystal protein, is a major component of 
eosinophils (Dyer and Rosenberg, 1996). Originally found to have affinity for galactosyl 
residues; this galectin shows higher affinity toward mannosyl residues (Dyer and 
Rosenberg, 1996; Swaminathan et al., 1999). This galectin is believed to be a mediator and 
potential biomarker of eosinophilic airway inflammation based on its accumulation within 
sputum (Chua et al., 2012), and in peripheral blood from patients suffering from bronchial 
inflammation (Devouassoux et al., 2008). 
Galectin-12 is a tandem-repeat galectin, typically expressed in leukocytes and adipose 
tissue that was cloned originally by Yang et al. (2001), and was found to impact the cell 
cycle of cancer cells. Although galectin-12 expression across most tissues is relatively 
weak, it is reported to have relatively high expression in acute promyelocytic leukemia 
(Timoshenko et al., 2016; Xue et al., 2016), and is involved with regulating adipocyte 
differentiation (Yang et al., 2004). 
1.4 Oxidative stress 
Oxidative stress can be defined as a disturbance in the balance between reactive oxygen 
species (ROS) production and antioxidant detoxification, leading to tissue damage 
(Betteridge, 2000). Maintaining a proper physiological redox status in a cell is crucial for 
cell survival and homeostasis. ROS may be produced by dedicated enzyme complexes i.e. 
NOX family of NADPH oxidases, or as by-products of oxidation-reduction reactions 
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(Janssen-Heininger et al., 2008; Murphy, 2009; Tochhawng et al., 2013). Induced oxidative 
stress can be achieved in vitro through exogenous administration of H2O2 or specific 
chemical inducers. For instance, 2-methyl-1,4-naphthoquinone (menadione) is a redox 
cycling compound that undergoes reduction via intracellular enzymes reducing molecular 
oxygen to a free radical superoxide anion (Criddle et al., 2006). Menadione has been shown 
to induce significant levels of H2O2 (Timoshenko et al., 1996). Additionally, the hypoxia 
mimetic agent, cobalt chloride (CoCl2) has been shown to induce ROS via a mechanism 
that is non-mitochondrial (Chandel et al., 1998; Kotake-Nara and Saida, 2007). Free 
radicals consist of one or more unpaired electrons making them extremely reactive with 
various cellular components including lipids, proteins, nucleic acids and carbohydrates in 
comparison to non-radicals (Halliwell, 1994; Tsukahara, 2007). Damage often occurs 
when the antioxidant defense system is inefficient or when ROS levels rise excessively, 
leading to free radical induced apoptosis. Often anti-apoptotic genes in certain cells appear 
to encode free radical scavengers i.e. glutathione or antioxidant enzymes i.e. glutathione 
peroxidase (GPX) or heme oxygenase 1 (ho-1) as a means to counter the stress (Dobashi 
et al., 2001; Sarafian and Bredesen, 1994). ho-1 catabolizes cellular heme into biliverdin 
carbon monoxide and free iron. It is strongly upregulated during oxidative stress and is 
documented as one of the sensitive and reliable markers of oxidative stress (Choi and Alam, 
1996; Poss and Tonegawa, 1997). Although an abundance of ROS may lead to oxidative 
damage; appropriate levels of ROS must be present to maintain physiological conditions. 
In fact, rapid ROS production known as oxidative “burst” is an important function of 
immune cells in which case large amounts of ROS are produced by oxidation of NADPH 
in order to combat foreign pathogens. Neutrophils and other phagocytes are often 
responsible and present at sites of inflammation in order to maintain healthy conditions. At 
the site of infection, neutrophils are the earliest of granulocytes recruited and release 
antimicrobial compounds from their granules in addition to the production of ROS in order 
to kill invading pathogens (van Gisbergen et al., 2005). 
Oxidative stress is clinically relevant and has been implicated in the development of 
various diseases/disorders, a short list of which include: cancer (Reuter et al., 2010), 
Alzheimer’s (Christen, 2000), Parkinson’s (Blesa et al., 2015), Huntington’s (Gil-Mohapel 
et al., 2014) cardiovascular diseases (Dhalla et al., 2000), autism (Chauhan and Chauhan, 
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2006), and depression (Michel et al., 2012). In the event of oxidative stress, the cell has 
numerous stress response mechanisms that have evolved in order to deal with increased 
ROS. Often, oxidative stress activates numerous signaling pathways that are involved with 
gene expression changes that ultimately govern the cells fate of either survival or death. 
ROS are known to activate pro-inflammatory signaling pathways causing the activation of 
mitogen-activated protein kinase (MAPK) dependent transcription factors including, NF-
ĸB, which following activation is translocated to the nucleus to modulate gene expression 
changes of several cytokines to induce apoptosis, inflammation and fibrosis (Bierhaus et 
al., 1997; Pugliese et al., 2015), and is well characterized within immune cells (Dumic et 
al., 2006). In particular, activation of MAPKs include a large number of serine/threonine 
kinases falling under the extracellular signal-regulated kinases (ERK), c-Jun N-terminal 
kinases (JNK), and p38 subfamilies, which are responsible for activation of various genes 
relevant for antioxidant defenses (Martindale and Holbrook, 2002). Further, oxidative 
stress has also been found to regulate transcription factors directly including: NF-ĸB 
(Gloire et al., 2006), p53 (Liu et al., 2008a), Nrf2 (Ma, 2013), HSF1 (Ahn and Thiele, 
2003), and others. In certain diseases, these factors promote cellular proliferation, 
apoptosis, transformation, angiogenesis, metastasis and activation of other signaling 
networks (Reuter et al., 2010). Another redox stress sensitive cascade includes the PP1-
JNK-Sp1 signaling pathway (Chu and Ferro, 2006; Ryu et al., 2003). Following activation 
via phosphorylation, the transcription factor Sp1 is translocated to the nucleus and binds 
GC-rich motifs of promoters augmenting transcription of genes relevant for stress 
responses (Ryu et al., 2003), cellular differentiation (Gong et al., 2014), proliferation 
(Zhang et al., 2014). Interestingly, galectins-1, -3, -10 and -12 have been reported to 
contain multiple potential Sp1 binding sites in their promoter region: indicating a common 
redox-sensitive regulatory factor and the potential for expression of these galectins to be 
influenced by oxidative stress (Dyer and Rosenberg, 2001; Hotta et al., 2001). 
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Figure 3. Redox sensitive PP1-JNK-Sp1 signaling pathway. Hydrogen peroxide 
inhibits PP1, which leads to the phosphorylation and subsequent activation of the Sp1 
transcription factor. Inducer of reactive oxygen species – menadione – is proposed to 
increase galectin gene expression via JNK signaling and Sp1 activation/binding.  
The above schematic demonstrates the PP1-JNK-Sp1 signaling pathway (interpreted from 
Chu and Ferro [2006]). Many galectin promoter regions have potential Sp1 binding sites 
and therefore this transcription factor is proposed in regulating galectin transcript 
expression. 
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Only recently, have galectins been analyzed more critically regarding their involvement 
with oxidative processes, redox status and related signaling mechanisms. Although many 
galectins share high sequence homology indicating similar biological function, there 
appears to be different regulatory mechanisms controlling their expression. This level of 
complexity makes it difficult to discern the precise function of each galectin across many 
cell types and conceptually as a whole considering there is often galectin functional 
redundancy. 
1.4.1 Galectin-1 – role in oxidative stress 
Galectin-1 is expressed in many tissues, primarily of mesodermal origin including: skeletal 
and smooth muscle, heart, liver, lung, spleen, kidneys and others (Klyosov, 2008). As 
mentioned previously galectin-1 has been reported to be redox-sensitive whereby its 
structure and subsequent function is altered via oxidation of free cysteine residues. This 
potentially explains why galectin-1 is mitogenic for various human cells including lymph, 
vascular and liver cells, while being an inhibitor of cell growth in neuroblastoma and 
connective tissue of bone marrow (Camby et al., 2006). A specific example includes 
oxidation of the three intramolecular disulfide bonds of galectin-1 allowing for a gain of 
CRD-independent effects leading to increased axonal regeneration in peripheral nerve but 
at the same time losing lectin binding associated functionality (Inagaki et al., 2000). A 
similar effect is demonstrated by Yu et al. (2015) whereby exogenously added oxidized 
human galectin-1 confers resistance toward oxidative stress in Molt4 cells compared to the 
reduced form of this galectin (Yu et al., 2015). Further, mouse galectin-2 is susceptible to 
oxidation by ROS resulting in loss of CRD-dependent function (Tamura et al., 2015). 
These data indicate that the manner in which galectin-1 confers its resistance may be 
dependent on its redox state. 
Aside from galectin-1 being structurally affected by the redox environment, this protein 
can also play a direct role in various oxidative processes. In fact, early studies demonstrated 
the potency of human and animal galectin-1, in addition to other galactoside-specific 
lectins to induce a respiratory burst from neutrophils (Timoshenko and Gabius, 1993; 
Timoshenko et al., 1997). Elola et al. (2005) reported that exogenously added pig spleen 
galectin-1 to white blood cells was able to activate polymorphonuclear leukocytes (PMN) 
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to produce significant levels of O2
•- when combined with other priming agents (Elola et 
al., 2005). Similarly, galectin-1 alone is able to activate extravasated human neutrophils to 
produce significant levels of O2
•-. Lin et al. (2015) demonstrated that galectin-1 can 
produce ROS by activating NADPH oxidase, which is important for wound healing in 
myofibroblasts (Lin et al., 2015). Interestingly, galectin-1 has been shown to promote 
angiogenesis and protect cancer cells from oxidative stress in a CRD-dependent fashion, 
which is attenuated by the disaccharide thiodigalactoside (TDG) (Ito et al., 2011). 
In addition to direct redox interactions, galectin-1 has also been reported playing a role 
within various oxidative stress/redox-sensitive signaling pathways. One example includes 
the interaction between galectin-1 and transforming growth factor (TGF-β). This growth 
factor is able to promote ROS by activating NADPH oxidase (Thannickal et al., 1998), and 
has been found to increase galectin-1 expression in a dose dependent manner (Daroqui et 
al., 2007). Further, galectin-1 has been reported to increase p38 and ERK expression in 
vitro (Chung et al., 2012; Maeda et al., 2004). Similarly, galectin-1 gene expression is 
down-regulated through the redox-sensitive ERK pathway evident by inhibition of 
MEK1/2 with inhibitors U0126 and SB202190 in activated T-cells (Fuertes et al., 2004). 
These findings show how galectin-1 expression is affected by both up- and down-stream 
components of these MAPK pathways. mTOR signaling is also oxidative stress sensitive 
(Heberle et al., 2015), and its downstream target molecule, P70S6 has been shown to 
increase galectin-1 expression (Fuertes et al., 2004). Galectin-1 has been shown to activate 
the JNK/c-Jun/AP-1 signaling pathway leading to apoptosis in T-cells (Brandt et al., 2010). 
This apoptotic effect was attenuated with the inhibitor SP600125, however, the role of JNK 
signaling on regulating galectin-1 gene expression has yet to be demonstrated. Evidence 
suggests JNK as a potential mediator of galectin-1 expression given its strong association 
with T-cell apoptosis (Zhu et al., 1999), and oxidative stress (Wang et al., 2008). 
Considering the strong association between oxidative stress and the pathogenesis of many 
diseases, galectin-1 is suggested as being a strong candidate biomarker of various stress 
responses. The interaction between galectin-1 and different signaling pathways suggest this 
protein as a major player within develop of diseases and its importance in mediating gene 
transcription of factors relevant for host defenses. 
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1.4.2 Galectin-3 – role in oxidative stress 
The role of galectin-3 regarding oxidative processes has been well documented. In fact, 
galectin-3 has been listed as a biomarker for many different diseases/conditions implicated 
with oxidative stress including thrombosis (Madrigal-Matute et al., 2014), heart failure 
(Erkilet et al., 2013; Medvedeva et al., 2016), various cancers (breast, kidney, thyroid and 
prostate) (Balan et al., 2012; Idikio, 2011), cardiac fibrosis (Martínez-Martínez et al., 
2014), and Alzheimer’s disease (Wang et al., 2015). It is no wonder then, why galectin-3 
is well studied considering its appeal across so many clinical paradigms. 
Similar to galectin-1, exogenously administered galectin-3 is also able to promote 
superoxide production by human neutrophils demonstrating the direct role of this galectin 
in oxidative processes (Almkvist et al., 2001; Karlsson et al., 1998). This oxidative burst 
by human neutrophils is induced following galectin-3 binding primarily the receptors 
CD66a and CD66b (Feuk-Lagerstedt et al., 1999). A similar effect has been demonstrated 
in mast cells whereby galectin-3 promotes oxidative stress-induced mast cells death via a 
CRD-dependent mechanism (Suzuki et al., 2008). Interestingly, this effect could not be 
replicated by galectin-1, indicating glycoreceptor-specific affinities for different galectin 
isoforms; dependent on cell type. Interestingly, galectin-3 has also been shown to 
potentially attenuate superoxide production via downregulation of priming factors 
suggesting that the specific role of this protein in either eliciting or inhibiting oxidative 
burst is cell context dependent (Cortegano et al., 1998). 
Galectin-3 regulation of and by redox signaling pathways has also been characterized. The 
promoter region of LGALS3 contains several regulatory elements including binding sites 
for AP-1 and NF-ĸB (Vasta and Ahmed, 2009). Interestingly, galectin-3 is has also been 
reported to stimulate the ERK/p38 and JNK pathways indicating galectin-3 can regulate 
and be regulated by these pathways (Filer et al., 2009). Further, Chen et al. (2006) report 
that mice knockout models for galectin-3 show decreased JNK1 protein and mRNA levels 
and a concurrent decrease in cytokine production, indicating the potential for galectin-3 to 
regulate this pathway at the transcriptional level (Chen et al., 2006). 
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1.4.3 Galectins-8, -9, -10 and -12 – role in oxidative stress 
Although the literature primarily indicates a strong association between galectins-1 and -3 
with oxidative processes and redox regulation, there is evidence of other galectins 
participating in these processes. 
Galectin-8 has also been shown to elicit superoxide anion production in primed human 
neutrophils, both intracellularly and extracellularly in a CRD-dependent manner (Carlsson 
et al., 2007). Furthermore, the levels of superoxide production are comparable to that of 
the potent chemotactic factor formylmethionyl-leucyl-phenylalanine (fMLP), which often 
serves as a positive control for neutrophilic oxidative burst (Nishi et al., 2003). The redox-
sensitive factors ERK and Akt act downstream of galectin-8 signal transduction (Romaniuk 
et al., 2010); however, the relation of this pathway to galectin-8 is not studied in the context 
of cellular stress. Additionally, little is known about the regulatory methods of this galectin 
both transcriptionally and translationally in the context of oxidative stress. However, many 
transcriptional isoforms of galectin-8 exist indicating the potential involvement of stress-
dependent splicing mechanisms. Considering widespread galectin-8 cell expression, 
further details should be identified for better understanding of this galectins role in a 
cellular stress context. 
Originally discovered in as a potent eosinophilic chemoattractant, galectin-9 has been 
reported as a key regulatory of autoimmune disease, in particular, by shifting both adaptive 
and innate immunity to an anti-inflammatory profile (Wiersma et al., 2013). Similar to 
galectin-8, galectin-9 is also a tandem-repeat galectin that consists of different spliced 
isoforms (Chabot et al., 2002), indicating its potential in having stress dependent splice 
variants. Vega-Carrascal et al. (2014) provide the only evidence of ROS production by 
human neutrophils, induced by galectin-9. The authors report that while galectin-9 alone 
was only able to promote superoxide production at supra-physiological levels, neutrophils 
primed prior to exposure to galectin-9 are more sensitive to superoxide production via 
NADPH oxidase (Vega-Carrascal et al., 2014). Redox-sensitive pathways have also been 
implicated in the regulation of galectin-9, and vice versa. In particular, inhibition of p38, 
but not JNK/c-Jun, significantly reduced expression of galectin-9 (Hsu et al., 2015). In 
contrast, JNK-induced galectin-9 expression has been detected in astrocytes indicating cell 
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type specific galectin-9 regulation (Steelman et al., 2013). Additionally, there is evidence 
of JNK pathway activation induced by galectin-9, indicating a role of galectin-9 working 
both up- and down-stream of this redox signaling pathway (Kobayashi et al., 2010). 
Prototypical galectin-10 has been reported in few molecular processes regarding oxidative 
stress and redox signaling. Selective binding preference of mannose by galectin-10 perhaps 
indicates receptor specific stress mediation. A deletion of the galectin-10 encoding gene in 
Caenorhabditis elegans revealed a protective role of this protein against oxidative stress 
(Nemoto-Sasaki and Kasai, 2009). However, no molecular signaling factors regarding 
galectin-10 gene expression nor factors impacted by galectin-10 have been identified.  
The more recently discovered galectin-12 has also been implicated in oxidative processes. 
Involvement of galectin-12 with adipocyte regulation and diminished insulin resistance 
suggests this tandem-repeat galectin may be a potential therapeutic target for metabolic 
syndrome and related disorders – all of which are highly impacted by elevation in reactive 
oxygen species. Unfortunately, few molecular mechanisms regulating or responding to 
galectin-12 have been documented. Galectin-12 has been reported to induce adipogenic 
signaling through increased expression of C/EBPs (Yang et al., 2004). Interestingly, these 
C/EBP transcription factors regulate the ROS producing enzyme NADPH oxidase, 
indirectly implicating the association of galectin-12 with oxidative burst (Manea et al., 
2014). Yang et al. (2004) also report galectin-12 expression is upstream of the oxidative 
stress sensitive ERK and Akt pathways (Yang et al., 2004). Additionally, ablation of 
galectin-12 expression was shown to diminish levels of nitric oxide secretion while 
reducing NF-ĸB and AP-1 expression, in macrophages (Wan et al., 2016). 
1.5 Cellular differentiation 
Cellular differentiation is a developmental process whereby cells become more specialized. 
For example, early stem cells may divide further into pluripotent stem cells, which can then 
give rise to various cell types within an organism. Mesenchymal stem cells (MSCs) from 
the bone marrow give rise to adipocytes and stromal cells (Beyer Nardi and da Silva 
Meirelles, 2006) whereas neural stem cells (NSCs) give rise to the nervous system and 
differentiate into neurons, astrocytes and other specialized neural cell types (Gage, 2000). 
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In particular, embryonic stem cells may further divide into hematopoietic stem cells 
(HSCs), which are stem cells that can give rise to over 10 distinct mature blood cell types 
through the process of hematopoiesis (Seita and Weissman, 2010). Although 
hematopoiesis occurs at embryonic development, this process is still present in adulthood 
to replenish the blood system (Jagannathan-Bogdan and Zon, 2013). Blood cells are 
divided into three lineages based on their respective differentiation patterns: erythrocytes 
consisting of oxygen carrying red blood cells, lymphocytes consisting primarily of T and 
B-cells important for immune function and promyelocytes, which give rise to granulocytes 
(basophils, eosinophils and neutrophils), and macrophages. Production of fully 
differentiated granulocytes and macrophages is dependent on induction by hematopoietic 
cytokines (Miranda and Johnson, 2007). Major cytokines responsible for differentiation 
primarily consist of colony-stimulating factors (CSFs), which are lineage specific 
glycoproteins that function as cytokines and interact with their cognate receptors on the 
surface of early progenitor cells within bone marrow (Barreda et al., 2004). Binding of 
cytokines to their respective receptors elicits multiple signaling pathways including: p38, 
JNK, ERK, JAK/STAT and PI3K/Akt. These pathways then activate transcription factors 
such as C/EBPs, cyclins, c-Myc and others relevant for myeloid differentiation (Miranda 
and Johnson, 2007). Differentiation is accompanied by selective increased expression of 
specific proteins. In particular, p47phox is one of many cytosolic components of 
superoxide producing enzyme, NADPH oxidase, that is upregulated in response to 
neutrophilic differentiation of HL-60 cells, and can therefore be considered a marker 
(Ellison et al., 2015). The expression of NADPH oxidase is important for fully functioning 
differentiated HL-60 (Chen et al., 2012). Further, knockout studies of this subunit have 
shown to decrease oxidative stress implicating its potential as a marker for both 
differentiation and oxidative processes (Landmesser et al., 2002; Pal et al., 2014). 
Interestingly, galectins have also been reported in playing a role within hematopoietic 
cellular differentiation. In fact, evidence suggests that elevated galectin expression occurs 
during the processes of differentiation and may act as a potential secondary mediator 
(Acosta-Rodríguez et al., 2004). The involvement of each galectin with differentiation is 
discussed below. 
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1.5.1 Galectin-1 – role in cellular differentiation 
Galectin-1 gene expression is implicated in myeloid cellular differentiation (Abedin et al., 
2003). Interestingly, the change in galectin-1 gene expression can vary depending on cell 
type and the inducer of differentiation. For example, treatment of different cells with 
differentiating agents have reported to decrease (Chiariotti et al., 1994), have no effect on 
(Abedin et al., 2003) or increase (Ohannesian et al., 1994) galectin-1 expression. 
Interestingly, exogenously added recombinant galectin-1 was shown to have a biphasic 
effect on hematopoietic cells by augmenting differentiation of promyelocytes into the 
granulocytic lineage at a low dose or inhibiting differentiation at a high dose (Vas et al., 
2005). This data indicates the complexity of galectin-1 as the low dose effect was 
dependent following CRD binding activity while the high dose was CRD-independent. 
Other studies have shown high galectin-1 expression during differentiation of HSCs along 
with other well-known factors (Silva et al., 2003).  
Although little information is present on regulatory mechanisms associated with galectin-
1 and hematopoietic cell differentiation; Liu et al. (2008) report that galectin-1 contributes 
to thymocyte differentiation and cell fate through transient activation of the ERK pathway 
(Liu et al., 2008b). Other results indicate that epigenetic mechanisms may contribute to 
galectin-1 expression. Methylation of the galectin-1 promoter at CpG clusters indicates one 
molecular mechanism governing modulation over the transcriptional activity of the 
galectin-1 gene (Benvenuto et al., 1996). Interestingly, inhibitors of DNA 
methyltransferases including 5-azacytidine (AzaC), and the less toxic 5-aza-2’-
deoxycytidine (decitabine) have been shown to increase cellular differentiation via removal 
of methyl groups on candidate promoters (Borodovsky et al., 2013; Turcan et al., 2013). In 
fact, lymphocytes treated with AzaC show a concomitant increase in galectin-1 gene 
expression followed by induction of hematopoietic cellular differentiation (Poirier et al., 
2001). 
1.5.2 Galectin-3 – role in cellular differentiation 
One unique feature of galectin-3 is its involvement in regulating cellular differentiation. 
This chimeric galectin mediates cellular differentiation of the hematopoietic lineage, 
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during both myeloid (Abedin et al., 2003), and lymphoid (Oliveira et al., 2009) 
hematopoiesis. Generally, it has been shown that endogenous levels of galectin-3 are 
strongly upregulated on the cell surface, binding primarily CD34, during myeloid cell 
differentiation (Le Marer, 2000). Increased galectin-3 expression has been observed during 
monocytic differentiation by human promyelocytes (Abedin et al., 2003), primary human 
monocytic differentiation into macrophages (Liu et al., 1995), and during T-cell 
differentiation (Vasil’eva et al., 2013). However, galectin-3 has also been shown to directly 
inhibit differentiation in non-hematopoietic cell types (Nakajima et al., 2014) making the 
function of this galectin during differentiation cell context dependent. In particular, 
differentiation of dendritic-cells decreased galectin-3 expression (Dietz et al., 2000). These 
opposing findings make galectin gene expression difficult to utilize as prognostic markers 
of general cell function (in this case differentiation). More evidence is needed to understand 
the role of galectin expression in response to or as possible mediators of differentiation.  
Galectin-3 has also been reported to be a regulator of differentiation. It’s 
expression/function directly inhibits osteoblast differentiation (Nakajima et al., 2014) 
while augmenting oligodendrocyte differentiation (Pasquini et al., 2011). Similarly, 
galectin-3 has been reported to inhibit granulocyte-macrophage colony stimulating factor, 
a cytokine important for inducing early stages of differentiation (Krugluger et al., 1997). 
In fact, the expression of galectin-3 may not only be important for inducing/augmenting 
differentiation into specific lineages: but by also inhibiting differentiation into other final 
cell fates. Acosta-Rodríguez et al. (2004) provide one example whereby knockdown of 
galectin-3 not only induced B-cell differentiation but also reduced the percentage of plasma 
cell differentiation (Acosta-Rodríguez et al., 2004). The opposing effects of galectin-3 
demonstrate its complexity during hematopoietic cellular differentiation and potential to 
be regulated by different networks suggesting different cell types maintain different 
regulatory methods for mediating galectin-3 expression. 
Epigenetic regulation has also been reported for galectin-3. Malignant prostate epithelial 
cells were shown to be sensitive to AzaC treatment displaying a marked increase in 
galectin-3 gene expression that was not seen within benign and malignant tissue (Ahmed 
et al., 2007). Similarly, various CpG islands within the transcription start site of the 
28 
 
LGALS3 gene suggest that the DNA methylations state of the galectin-3 gene is a potential 
biomarker for cancer (Keller et al., 2013; Ruebel et al., 2005). 
1.5.3 Galectins-8, -9, -10 and -12 – role in cellular differentiation 
Despite there being substantially less data on the galectins-8, -9, -10 and 12, there is 
literature indicating their involvement with differentiation.  
Similar to galectin-3, galectin-8 is able to promote T-cell differentiation by modulating 
cytokine activity through TGF-β signaling (Sampson et al., 2016). Although there is little 
literature on the involvement with galectin-9 and cellular differentiation, there is some 
evidence of transcript downregulation during monocytic differentiation (Abedin et al., 
2003). In contrast, upregulation of galectin-9 mRNA during monocytic differentiation has 
been reported making the role of this galectin during differentiation unclear (Harwood et 
al., 2016). Unrelated to hematopoietic differentiation, galectin-9 promotes MSC 
differentiation into chondrocytes through TGF-β signaling (Arikawa et al., 2009).  
Abedin et al. (2003) also reported an increase in galectin-10 transcript levels following 
neutrophilic differentiation of promyelocytes in vitro despite this galectin being expressed 
predominately in eosinophils (Abedin et al., 2003). Knockdown of galectin-10 expression 
during differentiation of eosinophil progenitors significantly inhibited granulogenesis 
indicating a novel role for galectin-10 during eosinophil development (Doyle and 
Ackerman, 2009). This galectin has large sequence and structure homology to galectins-1 
and -3 suggesting that it may also play a prominent role in hematopoietic cell 
differentiation (Ackerman et al., 1993). 
Galectin-12 has been reported in playing contrasting roles during cell differentiation. In 
particular, galectin-12 expression promotes adipocyte differentiation (Yang et al., 2004) 
while inhibiting neutrophilic differentiation of promyelocytes (Xue et al., 2016). 
Interestingly, however, ablation of galectin-12 in bone marrow cells did not affect their 
capability in differentiating into macrophages indicating the redundant function of other 
galectins in myeloid cell differentiation (Wan et al., 2016). Various factors thought to be 
involved with galectin-12 during cellular differentiation include vacuolar protein sorting 
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13 homolog C (VPS13C), C/EBP transcription factors and ERK1/2 pathways effecting NF-
ĸB and AP1 (Wan et al., 2016; Yang et al., 2004, 2016). 
1.6 Hypothesis 
The existing literature shows contrasting roles for galectins during cell differentiation and 
in response to oxidative stress. Interestingly, many of these galectins are expressed within 
certain tissue/cell types and most studies typically only examine a single galectin. 
Therefore, understanding galectin family expression patterns/profiles across different 
tissues is important for elucidating the overall synergistic, additive or antagonistic 
functions of galectins. Further, often altered galectin expression patterns are observed in 
response to different types of cell stress including: oxidative stress, hypoxia, nutrient 
deprivation, radiation and others (reviewed in Timoshenko, 2015). These findings suggest 
an importance of galectins in response to many types of pathological stress positioning 
galectins as possible therapeutic intervention targets. The overarching goal of my study is 
determine if galectins may be used as biomarkers of different types of cellular stress found 
within the tumour microenvironment by comparing galectin expression profiles in a 
leukemic cell line. 
The Timoshenko lab has recently demonstrated that the human promyelocytic leukemic 
HL-60 cell line is an excellent model to investigate stress-sensitive galectins (Timoshenko 
et al., 2016). HL-60 cells express 6 of the 12 known mammalian galectins and are easily 
differentiated in neutrophils when exposed to dimethyl sulfoxide (DMSO). My study 
specifically aims to identify the galectin expression profile of HL-60 cells exposed to both 
oxidative stress and DMSO-induced neutrophilic differentiation in an effort to establish a 
link between these two processes and identify potential molecular mechanisms responsible. 
Interestingly, Ogino et al. (2010) have reported that H2O2 is able to enhance neutrophilic 
differentiation of HL-60 cells despite not investigating any molecular mechanisms 
potentially responsible (Ogino et al., 2010). Thus altered expression of galectins in 
response to either oxidative stress or during differentiation may reveal overlapping 
regulatory mechanisms of galectin expression. 
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I hypothesize that oxidative stress responsive galectins are involved with HL-60 cell 
neutrophilic differentiation. The rationale behind this study is that both oxidative stress 
and cell differentiation are capable of producing altered galectin expression profiles. 
Objective 1: to determine the galectin expression profile of HL-60 under menadione-
induced oxidative stress and DMSO-induced neutrophilic differentiation. This will be done 
by RT-qPCR and immunoblotting techniques. 
Objective 2: To investigate the effect of galectin inhibitors on HL-60 cellular proliferation 
and neutrophilic differentiation. This will be done by determining the cell population 
doubling time through direct counts. Neutrophilic differentiation will be determined using 
a spectrofluorometric assay used to measure ROS production. 
Objective 3: To investigate the effect DNA methyltransferase inhibition and JNK signaling 
on galectin expression and during oxidative stress and neutrophilic differentiation. This 
will be done by RT-qPCR and immunoblotting techniques. 
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Chapter 2  
2 Materials and methods 
2.1 Cell culture 
Human promyelocytic leukemia suspension cell line HL-60 (ATCC® CCL­240™) was 
obtained from ATCC. Cells were cultured in Iscove’s Modified Dulbecco’s Eagles medium 
(IMDM) (Corning™) supplemented with 10% charcoal stripped fetal bovine serum (FBS) 
(Wisent Bioproducts), 100 IU/mL penicillin, 100 μg/mL streptomycin, in a humidified 
incubator at 37°C and 5% CO2. Cells were maintained under confluent conditions (1x10
6 
cells/mL) for all treatments and passaged accordingly. Cell viability was determined using 
a Leitz Z0124 microscope using a trypan blue (0.2%) exclusion test. 
2.2 Cell treatments 
To induce oxidative stress, HL-60 cells were treated with 10 μM menadione sodium 
bisulfite (Sigma-Aldrich) or 100 μM CoCl2 (Sigma-Aldrich) for 24 hrs. HL-60 neutrophilic 
differentiation was accomplished by treating cells with 1.3% DMSO for 72 hrs unless 
otherwise stated. Either 1 or 2.5 mM NAC (Sigma-Aldrich) was administered as an 
antioxidant for 24 hrs and 72 hrs for either oxidative stress or differentiation experiments, 
respectively. Global hypomethylation was accomplished using 50 nM DNA 
methyltransferase inhibitor 5-aza-2’-deoxycytidine (decitabine; Cayman Chemical) for 72 
hrs. Treatment with NAC or decitabine for 72 hrs included treating 3 times every 24 hrs 
from initial passage. Inhibition and activation of JNK was accomplished using 25 μM 
SP600125 (LG Labs), and 400 nM anisomycin (StressMarq), respectively for 24 hrs. 
Galectin inhibitors used included lactose (Sigma-Aldrich), N-acetyl-D-lactosamine 
(LacNac; Carbosynth), thiodigalactoside (TDG; Carbosynth), and galectin-1 specific 
inhibitor OTX008 (Axon Medchem). Mannose (Sigma-Aldrich), and α-methyl-D-
mannoside (α-MM; Sigma-Aldrich) were used as non-inhibitory sugars except for their 
specific affinity to galectin-10. 
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2.3 RNA extraction and cDNA synthesis 
Following cell treatment, cells were centrifuged and resuspended in Dulbecco’s Phosphate-
Buffered Saline (DPBS) without Ca2+ and Mg2+. Cells were then centrifuged, lysed with 
TRIzol® (Ambion), and RNA was isolated according to the manufacturer’s protocol. RNA 
was dissolved in water and quantified using a NanoDrop 2000c UV-Vis spectrophotometer 
(Thermo Fisher). Purity was assessed considering A260/280 of > 1.8 as the threshold. cDNA 
was reverse transcribed from 2 µg of RNA using the Maxima First Strand cDNA Synthesis 
Kit for RT-qPCR (K1671; Thermo Fisher) according to the manufacturer’s protocol. All 
primers were synthesized by BioCorp UWO OligoFactory (Western University, 
Department of Biochemistry). 
2.4 RT-PCR and RT-qPCR 
Primer information including sequence, amplicon size, cycling conditions and referencing 
is located in Appendix A: supplementary material. RT-PCR reaction mixtures consisted of 
2X Taq master mix (FroggaBio) mixed with nuclease–free water, 800 nM forward primer, 
800 nM reverse primer and 1 µL of cDNA template diluted 25 times. RT-PCR products 
were separated on a 2% agarose gel made with a 40 mM Tris, 20 mM acetic and 1 mM 
EDTA (TAE). Nucleic acids were stained using SYBR® Safe (Invitrogen), and imaged 
using a ChemiDoc XRS system (Bio-Rad). 
RT-qPCR for relative mRNA transcript levels were quantified using a SensiFAST™ 
SYBR® No-ROX Kit (Bioline) mixed with nuclease–free water, 400 nM forward primer, 
400 nM reverse primer, 0.5 µL of undiluted cDNA template and amplified with a CFX96™ 
Real-Time PCR Detection System (Bio-Rad). Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used as an internal control. Quantification of relative fold transcript levels 
was calculated using Livak’s 2-ΔΔCt or Pfaffl methodology to predict accurate gene 
expression levels based on realistic PCR amplification efficiencies. RT-qPCR using the 
Oxidative Stress RT2 Profiler PCR Array (PAHS-065Z; Qiagen) was performed as 
described by the manufacturer. 
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2.5 Antibodies 
Primary antibodies listed below were diluted in 50 mM Tris, 150 mM NaCl and 0.05% 
Tween-20 (TBS-T) supplemented with 5% bovine serum albumin (BSA), and 0.05% 
sodium azide. For western blotting purposes, the following primary antibodies were used: 
galectin-1 (1:200; sc-28248; Santa Cruz), galectin-3 (1:200; sc-20157; Santa Cruz), 
galectin-10 (1:10,000; ab-157475; AbCam), galectin-12 (1:200; sc-67294; Santa Cruz), 
SAPK/JNK (1:1000; 9252; Cell Signaling Technology), Phospho-SAPK/JNK (1:1000; 
9251; Cell Signaling Technology), and β-actin (1:200; sc-47778; Santa Cruz). Secondary 
antibodies include anti-rabbit IgG-HRP (1:10,000; sc-2004; Santa Cruz), and anti-mouse 
IgG HRP (1:10,000; sc-2005; Santa Cruz). 
2.6 Protein isolation and western blotting 
Following cell treatment, cells were centrifuged and resuspended in DPBS. Cells were then 
homogenized in a 2% SDS extraction buffer containing 50 mM Tris pH 7.5 supplemented 
with 1 mM PMSF and protease inhibitor cocktail containing 1 mM AEBSF, 5 mM EDTA, 
50 µM leupeptin and 1 µM pepstatin. Samples were then incubated on ice for an additional 
10 minutes before further homogenization via sonication with a Microson™ XL-2000 
Ultrasonic Liquid Processor (Qsonica) for 15 seconds at amplitude setting 2. Total protein 
concentration was determined using the DC Protein Assay™ (5000111; Bio-Rad) as per 
the manufacturer’s protocol and absorbance was measured at 595 nm by a Model 3550 
Microplate Reader (Bio-Rad). Protein extract (25 μg) was resolved by 15% SDS-PAGE 
and transferred onto PVDF membrane (Bio-Rad). Membranes were blocked with 5% BSA 
and 1% milk in TBS-T at room temperature for 1 hr before being probed with primary 
antibody overnight at 4°C. Membranes were then incubated with an appropriate 
horseradish peroxidase-conjugated secondary antibody (Santa Cruz), amplified with 
SuperSignal™ West Pico Chemiluminescent Substrate (34080; Thermo Fisher), and 
imaged with a ChemiDoc XRS system (Bio-Rad). Densitometry was performed using 
Image Lab™ software and significant differences were determined using SPSS considering 
p < 0.05 as the statistical threshold. 
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2.7 Measurement of fMLP-induced ROS production 
Cells were seeded at 0.5x106 cells/mL in 24 well plates and treated with 1.3% DMSO for 
72 hrs in order to achieve fully neutrophil-like differentiated HL-60 cells. Cells were then 
collected, centrifuged and resuspended in Hanks’ Balanced Salt Solution (HBSS) pre-
warmed to 37°C. Cells were loaded into a cuvette and absorbance was read at 600 nm in 
order to standardize cell concentration using NanoDrop 2000c spectrophotometer (Thermo 
Fisher). The cuvette was then loaded into an AMINCO-Bowman Series 2 Luminescence 
Spectrometer reading excitation and emission wavelengths at 380 and 460 nm, 
respectively. Cells were then exposed to 1 μM scopoletin (Sigma-Aldrich); a fluorescent 
substrate for 20 μg/mL horseradish peroxidase (HRP; Sigma) that is oxidized into non-
fluorescent products. A “cocktail” containing scopoletin and HRP was then added to the 
cuvette; producing fluorescence until a stable level is observed. To induce oxidative burst, 
100 nM fMLP was added to the cuvette. Scopoletin oxidation was measured as a decrease 
in fluorescent intensity. The subsequent kinetic data points were run through R using the 
algorithm described in Appendix A: Supplementary material to determine the point at 
which the slope (rate of H2O2 production) is greatest. Rate of H2O2 production was 
calculated as the maximal slope of recorded traces of scopoletin oxidation normalized to 
cell concentration and original fluorescent maximum (Fmax) presented as pmol/sec/1x10
6 
cells. 
2.8 Microscopy and nuclei staining 
HL-60 cell cultures were observed and imaged using an inverted Leica DM IL LED 
microscope in integrated modulation contrast (IMC) mode. To investigate cell nuclei, 
cytospins were prepared. Firstly, cells were resuspended in IMDM at 0.5x106 cells/mL, 
then centrifuged onto glass slides for 4 mins at 500 rpm using a Shandon’s Cytocentrifuge 
2. Cells were then fixed for 10 minutes using methanol and nuclei staining was performed 
using 2 µg/mL Hoechst-33342. Imaging of segmented nuclei to confirm cellular 
differentiation was done using an AxioImager A.1 fluorescent microscope (Carl Zeiss), 
and images were taken with a CCD camera Model XCD-X700 (Sony) using Northern 
Eclipse 8.0 software (Emprix Imaging Inc.). Scale bars were added using Northern Eclipse 
8.0 software. 
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2.9 Cell proliferation assay 
Cells were seeded at 0.1x106 cells/mL in 24 well plates and treated with different galectin 
inhibitors at various concentrations for 96 hrs. Cell count and viability were determined 
using a Leitz Z0124 microscope and using a trypan blue (0.2%) exclusion test every 24 
hours from initial seeding in order to determine cell doubling time. 
2.10 Statistical analysis 
All experiments were performed in at least triplicate unless otherwise stated and data are 
expressed as mean ± SD (unless stated otherwise). A one-way analysis of variance 
(ANOVA) followed by a Tukey’s HSD test were used to determine statistical significant 
differences across means. An independent samples t-test was used to compare means of 
treated groups vs. their respective control. Correlation analysis between genes was 
performed using a Pearson’s correlation test. Significant differences were determined using 
SPSS and GraphPad Prism 7 software considering p < 0.05 as the statistical threshold. 
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Chapter 3  
3 Results 
3.1 The galectin expression profile was differentially 
regulated in response to menadione-induced oxidative 
stress 
To determine the galectin expression profile, end-point PCR was performed to amplify 6 
of the 12 known human galectin genes expressed in HL-60 cells (Figure 4) (for reference 
see Appendix A: Supplementary material). The galectin mRNA expression profile was 
then determined for HL-60 cells treated with oxidative stress inducers: 10 μM menadione 
with or without 1 mM NAC and 100 μM CoCl2 for 24 hrs, using RT-qPCR (Figure 5). 
There was a statistically significant difference between treatment groups as determined by 
one-way ANOVA for LGALS1 (F4,1 = 21.6, p < 0.001), LGALS3 (F4,1 = 139.14, p < 0.001), 
LGALS9 (F4,1 = 13.77, p < 0.001), LGALS10 (F4,1 = 11.93, p < 0.01), and LGALS12 (F4,1 = 
8.74, p < 0.01). CoCl2 significantly increased LGALS1 (p < 0.05), and LGALS10 (p < 0.05) 
transcript expression only (Figure 5A, E) while significantly decreased (p < 0.001) 
expression of LGALS9 (Figure 5D). Similarly, transcript expression of LGALS1, LGALS3 
and LGALS10 was significantly up-regulated (p < 0.01, p < 0.001, p < 0.01 respectively) 
in response to menadione (Figure 5A, B, E), which was attenuated by the antioxidant NAC. 
Similar to the effect of CoCl2, menadione significantly decreased (p < 0.01) LGALS9 
expression that was also rescued by the addition of NAC (Figure 5D). Although treatment 
with menadione did not significantly increase LGALS12 transcript expression relative to 
the control; expression between menadione alone and menadione with NAC, was 
significantly different (p < 0.05) (Figure 5F), similar to the trend seen with LGALS1, 
LGALS3 and LGALS10. Interestingly, no significant differences in LGALS8 transcript 
levels were noticed across all treatments (F4,1 = 0.79, p > 0.05). 
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Figure 4. Verification of galectin gene PCR amplicons following RT-PCR by agarose 
gel electrophoresis. 
PCR products were resolved by a 2% agarose gel via electrophoresis and visualized by 
SYBR® Safe staining. Amplified products were of the expected sizes. Lane L (ladder), lane 
1 (LGALS1, 220 bp), lane 2 (LGALS3, 108 bp), lane 3 (LGALS8, 172 bp), lane 4 (LGALS9, 
91 bp), lane 5 (LGALS10, 82 bp), lane 6 (LGALS12, 111 bp), and lane 7 (GAPDH, 95 bp). 
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Figure 5. Oxidative stress altered HL-60 galectin transcript levels. 
∆∆Ct relative galectin transcript expression in HL-60 cells treated with 100 µM CoCl2, 10 
µM menadione and/or 1 mM NAC for 24 hrs relative to untreated cells, using RT-qPCR. 
(A) LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS10 and (F) LGALS12. 
GAPDH was used as an internal control. The data represent the mean ± SD, n = 3-6. 
Significant differences among treatments were determined using ANOVA followed by a 
Tukey’s HSD test considering *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 6. Oxidative stress altered HL-60 galectin protein levels. 
Immunoblot for galectin protein expression in (A) HL-60 cells treated with 10 µM 
menadione and/or 1 mM NAC for 24 hrs. Quantification of (B) galectin-1, (C) galectin-3, 
(D) galectin-10 and (E) galectin-12 protein levels by densitometric analysis of the 
immunoblot in (A). β-actin was used as a loading control. 25 μg of protein were loaded per 
well. The data represent the mean ± SD, n = 3. Significant differences among treatments 
were determined using ANOVA followed by a Tukey’s HSD test considering *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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Figure 7. Expression profiling of oxidative stress markers in HL-60 cells following 
menadione exposure. 
Cells were treated with 10 µM menadione for 24 hrs. (A) Oxidative Stress RT2 Profiler 
Array Kit using RT-qPCR. The data represent relative fold transcript levels (2-ΔΔCt) of 84 
genes (only candidate genes are shown) sensitive to oxidative stress, n = 1. (B) RT-qPCR 
for oxidative stress marker, p47phox, expression following treatment with 10 µM 
menadione for 24 hrs, relative to control cells. GAPDH was used as an internal control. 
The data is presented as the mean ± SD n = 3. *p < 0.05, **p < 0.01, ***p < 0.001. (C) Gel 
electrophoretic analysis of RT-PCR product for oxidative stress marker ho-1 (220 bp). 
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To confirm differences observed at the transcript expression, western blotting was 
performed to analyze protein levels (Figure 6). Significant differences were determined 
after densitometry analysis of bands. There was a statistically significant difference 
between treatment groups as determined by one-way ANOVA for galectin-3 protein levels 
(F3,1 = 25.44, p < 0.001), only. Densitometry analyses revealed a significant increase (p < 
0.001) in galectin-3 expression, which was attenuated by NAC exposure (Figure 6C). No 
significant differences were observed with galectin-1 (F3,1 = 1.64, p > 0.05) galectin-10 
(F3,1 = 1.3, p > 0.05), and galectin-12 (F3,1 = 0.9, p > 0.05) (Figure 6B, D, E). 
To further determine the menadione-induced oxidative stress response, RNA from HL-60 
cells treated with 10 μM menadione was analyzed using an RT-qPCR array kit for 84 genes 
related to oxidative stress (Figure 7). From this array, ho-1 and neutrophil cytosolic factor 
1 (p47phox) were picked as strong oxidative response candidates. ho-1 is a classic 
antioxidant protein product that cleaves heme while p47phox – typically a marker of 
oxidative stress – is more classically known as a marker of cellular differentiation. HL-60 
cells treated with 10 μM menadione exhibited p47phox expression as detected by RT-qPCR 
(Figure 7B). Gel electrophoresis following RT-PCR revealed a ho-1 amplicon of the 
correct size (Figure 7C), indicating that menadione-induced oxidative stress in HL-60 cells. 
3.2 The galectin expression profile was differentially 
regulated in response to DMSO-induced HL-60 
neutrophilic differentiation. 
Before determining the galectin expression profile for differentiated HL-60 cells, the 
neutrophilic phenotype was first confirmed. In order to differentiate HL-60 cells into 
neutrophil-like cells, cells were treated with 1.3% DMSO for 72 hrs. Differentiation was 
confirmed using 3 different techniques. Firstly, the rate of H2O2 production and cell 
viability was plotted versus time for 6 days (Figure 8A). Following cellular differentiation, 
HL-60 expresses fMLP receptors that bind fMLP subsequently activating oxidative burst, 
which was measured using a fluorometer. An increase and saturation of H2O2 production 
was observed at day 3 while cell viability remained ~80% (Figure 8A). Differentiation was 
further confirmed using both: 2 µg/mL Hoechst staining for segmented nuclei, 
characteristic of neutrophils (Campbell et al., 1995), and by inverted light microscopy to 
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reveal smaller cell and more rounded cell morphology (Figure 8B). Both smaller/rounded 
cells and multi-lobed nuclei were visible following 5 day exposure to 1.3% DMSO: 
indicative of cellular differentiation (Figure 8B). Finally, RT-qPCR analyses of the 
differentiation marker p47phox (Ellison et al., 2015) following 3 day treatment with 1.3% 
DMSO revealed a significant increase (p < 0.01) in transcript expression. These three 
techniques indicated prominent cellular differentiation following at least 72 hr exposure to 
1.3% DMSO. 
Following 72 hr treatment with 1.3% DMSO total RNA was isolated and analyzed for 
galectin transcript expression using RT-qPCR (Figure 9). There was a statistically 
significant difference between treatment groups as determined by one-way ANOVA for 
LGALS1 (F3,1 = 10.337, p < 0.01), LGALS3 (F3,1 = 76.5, p < 0.001), LGALS9 (F3,1 = 9.99, p 
< 0.01), LGALS10 (F3,1 = 75.69, p < 0.001), and LGALS12 (F3,1 = 16.16, p < 0.001). A 
significant increase in LGALS3 (p < 0.001), and LGALS10 (p < 0.001) (Figure 9B, E) 
transcript expression during differentiation was observed while LGALS12 (Figure 9F) was 
significantly downregulated (p < 0.01) compared to control cells. Interestingly, NAC 
partially attenuated DMSO-induced LGALS3 and LGALS10 transcript expression (p < 
0.001 and p < 0.01, respectively) (Figure 9B, E), indicating a redox dependent component 
during cell differentiation, which subsequently impacts galectin transcript expression. 
Similar to the result observed during oxidative stress; no significant differences were 
detected across all treatments for LGALS8 (F3,1 = 2.76, p > 0.05). Interestingly, LGALS1 
expression was significantly upregulated (p < 0.01) while LGALS9 expression was 
significantly downregulated (p < 0.01) when both 1.3% DMSO and NAC were 
administered together, however, induced no significant expression changes when either 
treatment was added alone (Figure 9A, D). 
To confirm differences seen at the transcript levels, western blotting was performed against 
individual galectins to analyze protein levels following 72 hr treatment with 1.3% DMSO 
(Figure 10). There was a statistically significant difference for galectin-1 (F3,1 = 12.01, p < 
0.01), galectin-3 (F3,1 = 103.41, p < 0.001), galectin-10 (F3,1 = 47.59, p < 0.001), and 
galectin-12 (F3,1 = 7.36, p < 0.05) between treatment groups as determined by one-way 
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Figure 8. Confirmation of DMSO-induced neutrophilic differentiation in HL-60 cells. 
Verification of HL-60 cell differentiation induced by 1.3% DMSO through: (A) fMLP 
induced H2O2 production 72 hrs post treatment, (B) cell morphology (upper panels), and 
nuclei staining (lower panels) with 2 µg/mL Hoechst of HL-60 control cells plated for 24 
hrs vs HL-60 cells following treatment with 1.3% DMSO for 120 hrs. Scale bars, 100 µm 
(light microscopy), and 25 µm (fluorescent microscopy). (C) RT-PCR and (D) RT-qPCR 
for differentiation marker, p47phox (93 bp) following treatment with 1.3% DMSO for 72 
hrs. GAPDH was used as an internal control. The data represent the mean ± SD, n = 3. 
Significant differences among treatments were determined using an independent samples 
t-test considering *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 9. Neutrophilic differentiation of HL-60 cells induced altered galectin 
transcript levels. 
∆∆Ct relative galectin transcript expression in HL-60 cells treated with 1.3% DMSO and/or 
2.5 mM NAC for 72 hrs relative to untreated cells, using RT-qPCR. (A) LGALS1, (B) 
LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS10 and (F) LGALS12. GAPDH was used 
as an internal control. The data represent the mean ± SD, n = 3-5. Significant differences 
among treatments were determined using ANOVA followed by a Tukey’s HSD test 
considering *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 10. Neutrophilic differentiation of HL-60 cells induced altered galectin 
protein levels. 
Immunoblots for galectin protein expression in (A) HL-60 cells treated with 1.3% DMSO 
and/or 2.5 mM NAC for 72 hrs. Quantification of (B) galectin-1, (C) galectin-3, (D) 
galectin-10 and (E) galectin-12 protein levels by densitometric analysis of the immunoblot 
in (A). β-actin was used as a loading control. 25 μg of protein were loaded per well. The 
data represent the mean ± SD, n = 3. Significant differences among treatments were 
determined using ANOVA followed by a Tukey’s HSD test considering *p < 0.05, **p < 
0.01, ***p < 0.001. 
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ANOVA. DMSO-induced neutrophilic differentiation significantly increased protein 
levels of galectins-1, -3, and -10 (p < 0.05, p < 0.001 and p < 0.01, respectively) (Figure 
10B, C, D) while significantly decreasing galectin-12 protein levels (p < 0.05) (Figure 
10E). Interestingly, only galectin-3 levels (Figure 10C) showed significant partial 
attenuation (p < 0.05) whereas the other galectins showed no attenuation. 
3.3 Inhibition of galectins suppressed cell proliferation and 
differentially affected neutrophilic differentiation of HL-60 
cells. 
To determine the effect galectins have on cellular proliferation of HL-60, competitive 
inhibition of galectins was achieved using both non-specific and specific CRD binding 
galectin inhibitors – using direct counts of cells in suspension cell culture (Figure 11). 
Inhibitors used included: lactose, LacNac, lactobionic acid, TDG, and OTX008. In 
addition, α-MM and mannose were used as negative controls considering these sugars are 
absent of β-galactosyl residues. There was a statistically significant difference between 
treatment groups for TDG (F4,1 = 12.6, p < 0.001), and OTX008 (F3,1 = 11.53, p < 0.001). 
Treatment with 40 mM TDG (p < 0.001), and 2.5 (p < 0.05) or 5 μM OTX008 (p < 0.001) 
significantly decreased HL-60 cell proliferation indicated by increased cell doubling times 
(Figure 11E, F). Although treatments with other inhibitors did not significantly slow cell 
proliferation, values showed a trend toward increased doubling time (Figure 11A, B, C, 
D). Inhibitors used at the indicated concentrations had no significant effect on cell viability 
Treatment with the same inhibitors was used to determine the role of galectins during 
neutrophilic differentiation (Figure 12) measured as the fold change in fMLP induced rate 
of H2O2 production. Cells were incubated with both differentiation agent 1.3% DMSO for 
72 hrs and a specific galectin inhibitor at the time of original seeding. There was a 
statistically significant difference across galectin inhibitor treatment groups when 
measuring H2O2 production (F6,1 = 82.039, p < 0.001). Although, treatment with lactose (p 
< 0.05), and lactobionic acid (p < 0.001) showed a significant increase in H2O2 production 
indicative of increased cellular differentiation; treatment with OTX008 significantly 
decreased (p < 0.001) H2O2 production indicative of decreased cellular differentiation 
(Figure 12). 
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Figure 11. Galectin-specific and non-specific inhibitory sugars increased HL-60 cell 
doubling time. 
Cell proliferation of HL-60 cells represented as the doubling time over 5 days treated with 
non-specific sugars such as (A) α-MM and (B) mannose and specific galectin inhibitors 
including (C) lactose, (D) lactobionic acid, (E) TDG and (F) OTX008. The data represent 
the mean ± SE n = 4-5. Significant differences among treatments were determined using 
ANOVA followed by a Tukey’s HSD test considering *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 12. Galectin-specific and non-specific inhibitory sugars differentially affected 
DMSO-induced HL-60 neutrophilic differentiation. 
Rate of H2O2 production (pmol/sec/1E6 cells, standardized to fold expression), as a 
measure of cellular differentiation induced by the chemotactic peptide 100 nM fMLP by 
HL-60 cells 72 hrs post treatment with 1.3% DMSO alone and in combination with various 
galectin inhibitors. The data represent the mean ± SD, n = 5-9. Significant differences 
among treatments were determined using ANOVA followed by a Tukey’s HSD test 
considering *p < 0.05, **p < 0.01, ***p < 0.001. 
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3.4 Modification of the redox environment impacted DMSO-
induced neutrophilic differentiation. 
In light of the observation that the antioxidant NAC impacted galectin expression during 
neutrophilic differentiation; I sought to test the effect of both oxidative stress inducer 
menadione and NAC on HL-60 neutrophilic differentiation as measured by fMLP induced 
H2O2 production (Figure 13A, B). There was a statistically significant reduction in DMSO-
induced differentiation following NAC treatment (Figure 13A) (F3,1 = 41.54, p < 0.001), 
(Figure 13B) (F5,1 = 125.73, p < 0.001) as determined by one-way ANOVA. DMSO (1.3%) 
administered in conjunction with 2.5 mM NAC for 72 hrs showed a significant decrease (p 
< 0.001) in H2O2 production rates in comparison to the positive control indicating that 
quenching ROS during differentiation was able to diminish levels of the neutrophilic 
phenotype (Figure 13A). Interestingly, adding 0.65% DMSO in conjunction with 10 μM 
menadione did not significantly increase levels of H2O2 compared to 0.65% alone (Figure 
13B). However, the antioxidant NAC was still capable of significantly decreasing levels of 
H2O2 produced by 0.65% DMSO alone (p < 0.05), and in conjunction with 10 μM 
menadione (p < 0.01) (Figure 13B). Complete attenuation of H2O2 production similar to 
untreated levels was not observed, indicating a small synergistic effect of 0.65% DMSO 
with 10 μM menadione (Figure 13B). 
3.5 DNA methylation regulated galectin transcript and 
protein levels in HL-60 cells. 
DNA demethylation has been reported to induce cellular differentiation of HL-60 cells 
(Schwartsmann et al., 1987); therefore, I sought to investigate the effect of DNA 
methylation on galectin gene expression by using decitabine – an inhibitor of DNA 
methyltransferases. HL-60 RNA was isolated for RT-qPCR following treatment with 50 
nM decitabine and/or 0.65 – 1.3% DMSO for 72 hrs to determine relative p47phox 
transcript levels (Figure 14B). Treatment with 50 nM decitabine showed a significant 
increase (p < 0.05) in p47phox expression indicating the potential for this drug to increase 
HL-60 cell differentiation (Figure 14A). Interestingly, co-treatment with 0.65% DMSO 
and 50 nM decitabine displayed a synergistic effect on p47phox induction in comparison  
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Figure 13. Modification of the redox environment changes the HL-60 final 
differentiated phenotype. 
Rate of H2O2 production as a measure of cellular differentiation induced by the chemotactic 
peptide 100 nM fMLP by HL-60 cells 72 hrs post treatment with 0.65 – 1.3% DMSO alone 
and in combination with 10 μM menadione or 2.5 mM NAC, or both. Panels (A) and (B) 
represent individual experiments under different treatments. Significant differences among 
treatments were determined using ANOVA followed by a Tukey’s HSD test and are 
represented as different letters, considering p < 0.05. The data represent the mean ± SD, n 
= 3-5. 
  
61 
 
 
 
 
  
A 
B 
62 
 
Figure 14. Inhibition of DNA methyltransferases upregulated the differentiation 
marker, p47phox. 
∆∆Ct relative p47phox transcript levels in HL-60 cells treated with (A) 50 nM decitabine 
for 72 hrs or (B) 0.65 – 1.3% DMSO with or without 50 nM decitabine relative to untreated 
cells, using RT-qPCR. GAPDH was used as an internal control. The data represent the 
mean ± SD, panel (A) n = 3, (B) n = 1. Significant differences among treatments were 
determined using ANOVA followed by a Tukey’s HSD test considering *p < 0.05, **p < 
0.01, ***p < 0.001. 
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Figure 15. Inhibition of DNA methyltransferases induced changes in galectin 
transcript and protein levels. 
(A) ∆∆Ct relative galectin transcript expression in HL-60 cells treated with 50 nM 
decitabine relative to untreated cells, using RT-qPCR. The data represent the mean ± SD, 
n = 3-4. Significant differences between treatments were determined using an independent 
samples T-test considering *p < 0.05, **p < 0.01, ***p < 0.001. GAPDH was used as an 
internal control. (B) Immunoblots for galectin protein expression in HL-60 cells treated 
with 50 nM decitabine for 72 hrs. β-actin was used as a loading control. The data represent 
the mean ± SD, n = 3. (C) Quantification of galectin levels by densitometric analysis. 
Significant differences among treatments were determined using ANOVA followed by a 
Tukey’s HSD test considering *p < 0.05, **p < 0.01, ***p < 0.001. 
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to treatment with either 0.65% DMSO or 50 nM decitabine, alone (Figure 14B). Therefore, 
decitabine works synergistically with DMSO to induce the differentiated phenotype. 
The HL-60 galectin expression profile was determined following treatment with 50 nM 
decitabine at both the transcript and protein level (Figure 15). There was a statistically 
significant difference between galectins (F5,1 = 67.14, p < 0.001) following treatment with 
50 nM decitabine as determined by one-way ANOVA. Treatment with decitabine 
significantly increased LGALS1, LGALS3, LGALS10 and LGALS12 transcript levels (p < 
0.001, p < 0.05, p < 0.05 and p < 0.01, respectively) (Figure 15A). Additionally, a 
significant decrease in expression (p < 0.05) was observed with LGALS9 (Figure 15A). 
There was a statistically significant change across galectin protein expression levels (F3,1 = 
33.56, p < 0.001) following treatment with 50 nM decitabine as determined by one-way 
ANOVA. Western blots showed a significant increase of galectin-1, -3, and -10 expression 
(p < 0.05, p < 0.001 and p < 0.01, respectively) (Figure 15B, C). Interestingly, an increase 
in galectin-12 expression was not observed at the protein level (Figure 15B, C). 
3.6 The JNK signaling pathway was differentially regulated 
in response to oxidative stress and HL-60 neutrophilic 
differentiation and regulates galectin transcript levels. 
The effect of JNK signaling on galectin transcript levels was investigated using the JNK 
inhibitor SP600125 (Figure 16A), and activator anisomycin (Figure 16B) followed by RT-
qPCR analysis. Significant differences in galectin transcript levels were determined 
following treatment with SP600125 (F5,1 = 22.579, p < 0.001), and anisomycin (F5,1 = 
112.39, p < 0.001) as indicated by one-way ANOVA. Interestingly, inhibition of JNK 
signaling increased LGALS1 and LGALS12 transcript levels (p < 0.01 and p < 0.05, 
respectively), and significantly decreased LGALS8, LGALS9 and LGALS10 levels (p < 
0.01, p < 0.001 and p < 0.001, respectively) (Figure 16A). Activation of JNK signaling 
increased expression of LGALS1, LGALS3 and LGALS8 (p < 0.05, p < 0.01 and p < 0.01, 
respectively) while significantly decreased LGALS9 and LGALS12 expression (p < 0.05 
and p < 0.05, respectively) (Figure 16B). These data indicate that galectins are 
differentially regulated by the JNK signaling pathway and that other signaling pathways 
(i.e. MAPKs) may also regulate galectin expression as a compensatory response. 
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Figure 16. JNK signaling altered galectin levels and was differentially regulated 
during oxidative stress and DMSO-induced neutrophilic differentiation. 
∆∆Ct relative galectin transcript levels in HL-60 cells treated with either JNK inhibitor (A) 
25 μM SP600125 or activator (B) 400 nM anisomycin, respectively for 24 hrs, relative to 
untreated cells using RT-qPCR. The data represent the mean ± SD, n = 3. Significant 
differences between treatments were determined using an independent samples T-test 
considering *p < 0.05, **p < 0.01, ***p < 0.001. Immunoblots for phosphorylated JNK 
and total JNK levels in HL-60 cells treated with (C) 10 μM menadione with or without 1 
mM NAC for 24 hrs (D) 1.3% DMSO with or without 2.5 mM NAC for 72 hrs, n = 3. 
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To determine endogenous phosphorylated JNK levels during oxidative stress and DMSO-
induced neutrophilic differentiation, western blotting for phosphorylated JNK and total 
JNK was performed. Oxidative stress increased phosphorylated JNK levels, which were 
attenuated with NAC (Figure 16C). In contrast, differentiation of HL-60 was accompanied 
by decreased phosphorylated JNK levels (Figure 16C). 
3.7 Correlative analysis between galectins, oxidative stress 
and cellular differentiation suggest galectins as 
biomarkers of cellular stress responses. 
To identify a specific correlation between galectins, oxidative stress and cellular 
differentiation a Pearson’s correlation was computed based on treatments with 1.3% 
DMSO, 10 µM menadione, 50 nM decitabine, 25 µM SP600125 and 400 nM anisomycin. 
This test measures the strength of linear association between two genes. ho-1 was used as 
a marker of menadione-induced oxidative stress while p47phox was used as marker of 
cellular differentiation. The Pearson’s correlation test revealed a significant positive 
correlation in the expression of oxidative stress marker ho-1 with LGALS1 (p < 0.05, R2 = 
0.400, n = 15), LGALS3 (p < 0.001, R2 = 0.756, n = 15), and LGALS8 (p < 0.01, R2 = 0.570, 
n = 15) while a significant negative correlation was observed with LGALS12 (p < 0.01, R2 
= 0.426, n = 15) (Figure 17A, B, C, F). 
Correlations were also determined between transcript levels of the cellular differentiation 
marker p47phox and galectins (Figure 18). In particular, there was a significant positive 
correlation of expression of p47phox with LGALS3 (p < 0.001, R2 = 0.723, n = 12), LGALS9 
(p < 0.05, R2 = 0.424, n = 12), and LGALS10 (p < 0.001, R2 = 0.868, n = 12) while a 
significant negative correlation was observed with LGALS1 (p < 0.001, R2 = 0.691, n = 
12), and LGALS12 (p < 0.05, R2 = 0.456, n = 12) (Figure 18A, B, D, E, F). 
Correlations between transcript levels of individual galectins were also tested to determine 
expression patterns and the possibility for expression redundancy, across all treatments 
(Figure 19). Pearson’s correlation analyses identified a significant correlation between 
LGALS1 with LGALS3 (p < 0.05, R2 = 0.302, n = 15), LGALS8 (p < 0.01, R2 = 0.547, n = 
15), and LGALS12 (p < 0.01, R2 = 0.641, n = 12) while a significant negative correlation 
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Figure 17. Correlation in transcript levels between galectins and the oxidative stress 
marker ho-1. 
∆∆Ct relative galectin and ho-1 transcript levels in HL-60 cells treated with (●) 1.3% 
DMSO, (■) 10 µM menadione, (▲) 50 nM decitabine, (▼) 25 µM SP600125 and (◆) 400 
nM anisomycin, (A) LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS10 and 
(F) LGALS12. GAPDH was used as an internal control. Significant correlation between 
genes was determined using the Pearson’s correlation test considering p < 0.05, n = 3 for 
each treatment. 
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Figure 18. Correlation in transcript levels between galectins and marker of HL-60 
cell neutrophilic differentiation p47phox.  
∆∆Ct relative galectin and p47phox transcript levels in HL-60 cells treated with (●) 1.3% 
DMSO, (■) 10 µM menadione, (▲) 50 nM decitabine, (▼) 25 µM SP600125 and (◆) 400 
nM anisomycin. (A) LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS10 and 
(F) LGALS12. GAPDH was used as an internal control. Significant correlation between 
genes was determined using the Pearson’s correlation test considering p < 0.05, n = 3 for 
each treatment. 
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Figure 19. Correlation between galectin transcript levels. 
∆∆Ct relative galectin transcript levels in HL-60 cells treated with (●) 1.3% DMSO, (■) 
10 µM menadione, (▲) 50 nM decitabine, (▼) 25 µM SP600125 and (◆) 400 nM 
anisomycin. Correlations were made between each individual galectin vs.: (A–D) LGALS1, 
(E–G) LGALS3, (H–I) LGALS8, (J) LGALS9 and (K) LGALS12. GAPDH was used as an 
internal control. Significant correlation between gene expressions was determined using 
the Pearson’s correlation test considering p < 0.05, n = 3 for each treatment. 
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Figure 20. Correlation between oxidative stress and cellular differentiation. 
∆∆Ct relative ho-1 and p47phox transcript levels in HL-60 cells treated with (●) 1.3% 
DMSO, (■) 10 µM menadione, (▲) 50 nM decitabine and (▼) 25 µM SP600125. GAPDH 
was used as an internal control. Significant correlation between genes was determined 
using the Pearson’s correlation test considering p < 0.05, n = 3 for each treatment. 
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was observed with LGALS9 (p < 0.01, R2 = 0.422, n = 15) (Figure 19A, B, C, D). When 
correlating galectin transcript levels with LGALS3, there was a significant positive 
correlation with LGALS8 (p < 0.001, R2 = 0.659, n = 15), and LGALS9 (p < 0.05, R2 = 
0.390, n = 12) while a significant negative correlation was observed with LGALS12 (p < 
0.001, R2 = 0.851, n = 12) (Figure 19E, F, G). Further, the Pearson’s correlation analyses 
identified a significant negative correlation between LGALS8 with LGALS9 levels (p < 
0.05, R2 = 0.382, n = 15), and LGALS12 (p < 0.05, R2 = 0.328, n = 15) (Figure 19H, I). This 
test also revealed a significant positive correlation between LGALS9 with LGALS10 
expression (p < 0.05, R2 = 0.405, n = 12) (Figure 19J). Finally, the Pearson’s correlation 
analyses identified a significant positive correlation between LGALS10 and LGALS12 
expression (p < 0.001, R2 = 0.693, n = 15) (Figure 19K). 
Lastly, to identify a link between oxidative stress and cellular differentiation, a Pearson’s 
correlation test was computed to determine their relationship (Figure 20). This test 
identified a significant positive correlation between oxidative stress marker, ho-1 and the 
cellular differentiation marker, p47phox (p < 0.001, R2 = 0.882, n = 12) (Figure 20). 
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Chapter 4  
4 Discussion 
The findings of my study demonstrate that oxidative stress sensitive galectins are involved 
with HL-60 neutrophilic differentiation. The first objective utilized immunoblotting and 
RT-qPCR techniques to define galectin-1, -3 and -10 as key stress-sensitive galectins that 
are similarly regulated under oxidative stress and neutrophilic differentiation. Additionally, 
the other galectins indicate minor similarities and differences between expression profiles 
of HL-60 including differential regulation of galectin-9 and -12. Competitive galectin 
inhibition with inhibitory sugar TDG and the selective small-molecule inhibitor OTX008 
were used to investigate the second objective and demonstrate the relevance of galectins in 
promoting cellular proliferation. Similarly, both galectin-specific and non-specific 
inhibitory sugars differentially effected H2O2 production by HL-60 cells indicating 
galectins are involved with both the promotion and potential inhibition of DMSO-induced 
neutrophilic differentiation. Investigation of the third objective with immunoblotting and 
RT-qPCR techniques revealed the direct effect of DNA hypomethylation and JNK 
signaling on upregulating galectin transcript levels. Inhibition of DNA methyltransferases 
increased the same stress-sensitive galectins (LGALS1, LGALS3, and LGALS10) regulated 
during oxidative stress and differentiation. Immunoblotting for JNK levels indicate that 
this pathway is differentially regulated under oxidative stress and neutrophilic 
differentiation despite these two processes inducing similar galectin expression profiles. 
4.1 Interpretation 
4.1.1 Oxidative stress and neutrophilic differentiation induce similar 
galectin expression profiles. 
There is a precedent for increased galectin expression during oxidative stress. Specifically, 
galectin-1 and -3 have been shown to display a protective role against the harmful effects 
of increased ROS production (Ito et al., 2011; Martínez-Martínez et al., 2014). However, 
the role of increased galectin expression following oxidative stress may also be related to 
these proteins being involved with apoptotic pathways. Galectin-3, for example, has been 
reported to both induce (Xue et al., 2013), and inhibit (Hoyer et al., 2004) apoptosis in 
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lymphocytic cell lineages. However, Matarrese et al. (2000) showed that overexpression 
of galectin-3 in breast cancer cells provides a protective effect from menadione-induced 
ROS, suggesting antioxidant-like properties of galectin-3 (Matarrese et al., 2000). The 
decreased expression of LGALS9 is probably related to its often down-regulated expression 
within tumour cells (which undergo cellular stress including oxidative stress) in 
comparison to normal cells (Heusschen et al., 2013). However, signals related to 
inflammatory responses such as LPS have been reported to elevate galectin-9 mRNA 
levels, indicating stress-specific expression of this galectin (Kasamatsu et al., 2005). 
Increased expression of LGALS1, LGALS3 and LGALS10 during oxidative stress indicate 
a common regulatory method amongst these galectins (Figure 5). In particular, Sp1 has 
been suggested to regulate transcription of these galectins considering the many possible 
Sp1 transcriptional binding spots amongst their promoters (Dyer and Rosenberg, 2001). 
Additionally, Sp1 has been identified as a redox-sensitive transcription factor (Chu and 
Ferro, 2006). Specifically, activation of the PP1-JNK-Sp1 signaling pathway via ROS 
promotes the phosphorylation and subsequent activation (and translocation to the nucleus) 
of transcription factor Sp1 (Chu and Ferro, 2006). Although LGALS9 was generally 
downregulated in my study (Figure 5 and Figure 9); this galectin has been reported being 
involved with many of the same stress sensitive pathways that increase galectin transcript 
levels indicating galectin regulatory mechanism overlap (Laderach et al., 2010). The stable 
expression of LGALS8 is interesting considering its vast differential expression across 
many different normal and tumour lines (Elola et al., 2014; Lahm et al., 2001). 
Unfortunately, little is known about LGALS8 regarding the transcriptional and translational 
machinery with respect to stress-sensitive models (Timoshenko, 2015). Similarly, despite 
evidence suggesting involvement of LGALS12 redox-sensitive pathways (Yang et al., 
2004), little is known about this galectin with respect to regulatory methods involved with 
cell stress. Although this galectin is reported to play a role within adipose tissue 
development, its expression is influenced among insulin-signaling, oxidative stress and 
inflammatory-related signaling pathways (Li et al., 2010). 
The expression changes associated with DMSO-induced neutrophilic differentiation of 
HL-60 cells are interesting for two reasons. First, the expression pattern observed during 
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differentiation was markedly stronger than that of oxidative stress (Figure 9). And second, 
generally, the expression pattern – in regards to down- and up-regulation of galectins – was 
similar to that of oxidative stress. Specifically, there is an upregulation with LGALS3 and 
LGALS10 that was also observed at the protein level with galectin-1. This indicates the 
potential for an association between oxidative stress and neutrophilic differentiation based 
on galectin expression patterning. Partial attenuation of LGALS3 and LGALS10 expression 
following NAC administration with DMSO-induced differentiation is in accordance with 
another study showing NAC supplementation reduces differentiation marker expression 
during HL-60 differentiation (Krance et al., 2010). Complete attenuation was not achieved 
suggesting that other molecular mechanisms are at play for galectin expression. For 
example, both galectin-1 and galectin-3 are involved with regulating apoptosis in T-cells 
(Stillman et al., 2006), a process that is commonly associated with the development of 
immune cells (Opferman, 2008). The similar expression pattern observed between 
galectin-1, -3 and -10 can be expected considering the high level of amino acid sequence 
homology specifically between these galectins (Leonidas et al., 1995). Non-varying 
expression of LGALS8 during cellular differentiation is expected considering its expression 
has been shown to be stable during eosinophil-, monocyte- and neutrophil-like 
differentiation of HL-60 cells (Abedin et al., 2003). The following expression profiles 
indicate the potential for galectins as targets in disease diagnosis, prognosis and clinical 
therapeutic models. Unfortunately, therapeutic strategies associated with acute myeloid 
leukemia (AML) have reached their limit of effectiveness (Zhou et al., 2013). Considering 
the strong association between ROS and hematopoietic stem cell differentiation, galectins 
may represent ideal candidates for targeted treatment against AML. 
4.1.2 Galectin-specific and non-specific inhibitory sugars and 
modification of the redox environment using NAC decreased 
cellular proliferation and impacted the HL-60 cell differentiated 
phenotype. 
The use of galectin inhibitors on HL-60 cell proliferation showed varied results. Although 
all sugars showed a trend toward decreased cell proliferation in a dose-dependent manner; 
only TDG and OTX008 significantly increased the cell doubling time (Figure 11E, F). Both 
of these inhibitors are known to inhibit galectin-1 suggesting this galectins involvement 
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with cellular proliferation. Galectin-1 has been show to demonstrate conflicting roles 
during cell proliferation depending on its localization and cell type. In particular, 
extracellular galectin-1 has been reported to bind α5β1 integrin in order to inhibit cellular 
proliferation through increased Sp1 transactivation in carcinoma cell lines (Fischer et al., 
2005), while intracellular galectin-1 can enhance cell proliferation through protein-protein 
interactions with RAS (Prior et al., 2003). The effect on cell proliferation observed with 
the galectin-1 inhibitor OTX008, has also been reported to inhibit endothelial cell 
proliferation (Dings et al., 2006). OTX008 is unable to affect galectin-1s interaction with 
ECM components but rather its proposed mechanism of action is through regulating 
galectin-1 interaction with intracellular components involved with cell cycle components 
directly (Astorgues-Xerri et al., 2014). Since lactose exhibited no inhibitory effect despite 
its reported relatively low dissociation constant value (Kd) with galectin-1 at 12.4 µM in 
HL-60 cells and 64 µM in bovine tissue and with galectin-3 at 55.2 µM (Schwarz et al., 
1998; Stowell et al., 2008), these galectins then may mediate cellular proliferation through 
CRD-independent interactions. Interestingly, Cedeno-Laurent et al. (2012) demonstrate 
that lactose attenuates the modulatory effect of galectin-1 on cell proliferation in T-cells 
further indicating that the effect of galectin-1 on cell proliferation is cell type dependent 
(Cedeno-Laurent et al., 2012). TDG demonstrated an inhibitory effect on HL-60 cellular 
proliferation (Figure 11E). TDGs effect on HL-60 cell proliferation can be attributed to – 
unlike lactose – its stronger binding affinity to galectin-1 and -3 with Kd values of 24 µM 
and 43 µM, respectively, and increased metabolic stability (van Hattum et al., 2013). 
Maeda et al. (2003) report similar results whereby galectin-1 and -3 stimulate hepatic cell 
proliferation through activation of the ERK pathway and this effect was attenuated by TDG 
(Maeda et al., 2003). α-MM and mannose were used to assess their potential inhibition of 
galectin-10 during cellular proliferation. My results indicate that despite galectin-10s 
preferential binding for mannosyl residues over galactosyl residues, galectin-10 does not 
contribute to cellular proliferation of HL-60 in a CRD-dependent way (Figure 11A, B). 
Galectin-8 maintains a lower binding avidity (Kd = 130 µM–150 µM) toward lactose 
compared to the other galectins (Hirabayashi et al., 2002; Ideo et al., 2003). Interestingly, 
Cattaneo et al. (2011) provide evidence that both lactose and TDG inhibited galectin-8 in 
peripheral blood mononuclear cells (PBMCs) at concentrations of 50 mM and 30 mM, 
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respectively (Cattaneo et al., 2011). Similarly, 50 mM lactose was used to inhibit 
recombinant galectin-3 stimulated cell proliferation in fibroblasts (Inohara et al., 1998), 
and preadipocytes (Kiwaki et al., 2007). Thus, HL-60 cell proliferation may not be 
inhibited by lactose at my experimental concentrations despite relatively low dissociation 
constants whereas TDG falls within my tested range (Figure 11C, E). 
OTX008 was able to decrease fMLP induced H2O2 production indicating that the 
expression of galectin-1 is important for the process of differentiation (Figure 12). 
Galectin-1 expression has been reported to play a role in the differentiation of dendritic 
cells (Fulcher et al., 2009), thymocytes (Liu et al., 2008b), and both B- and T- cells (Espeli 
et al., 2009; Liu et al., 2009). Interestingly, TDG did not have an effect on neutrophilic 
differentiation despite its ability to inhibit galectins, which mediate cellular proliferation. 
Thus, the expression of other galectins including -3, -10 and -12 may be associated with 
the direct effect of differentiation including apoptosis, cycle arrest and the indirect effect 
of cytotoxicity induced by DMSO. Interestingly, ~30% of cells are apoptotic following 
cellular differentiation through the activation of caspases and MAPK pathways (Duval et 
al., 2006). My findings indicate no change in differentiation following the addition of TDG 
after DMSO-induced differentiation (Figure 12) despite an inhibitory effect of this drug on 
T-cell differentiation (de la Fuente et al., 2014). T-cell differentiation is reported to be 
dependent on galectin-1 binding to CD69 (de la Fuente et al., 2014). Considering OTX008 
inhibited differentiation while TDG did not, HL-60 neutrophilic differentiation may be, in 
part, mediated through CRD-independent function of galectin-1. Surprisingly, lactose and 
lactobionic acid treatment induced increased levels of ROS production indicating 
“enhanced” neutrophilic differentiation and the potential for galectins to have an inhibitory 
effect on differentiation (Figure 12). One similar example includes galectin-3s ability to 
inhibit osteoblast differentiation, which was attenuated via the addition of lactose 
(Nakajima et al., 2014). Additionally, galectin-12 is downregulated following neutrophilic 
differentiation of promyelocytes indicating that lactose and lactobionic acid may be 
inhibiting galectin-12 expression and subsequently increasing differentiation (Xue et al., 
2016). The extent of which some inhibitors work while others do not remains elusive; 
however, differences between the binding affinities for these inhibitors toward all galectins 
may provide an explanation for the varying effect on differentiation. Additionally, 
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determining the glycoreceptor content/profile/structure on the cell surface of HL-60 would 
provide more details as to which glycans represent a significant binding partner to certain 
galectins over others. 
To better understand the role of oxidative stress and its potential association with 
neutrophilic differentiation, modification of the redox environment using menadione and 
NAC during differentiation was investigated. My results indicate that menadione, a redox 
cycling compound was unable to “enhance” neutrophilic differentiation. Ogino et al. 
(2010) reported an enhanced effect during differentiation when using the direct oxidant: 
H2O2 (Ogino et al., 2010). Typically, reductive enzymes including NADPH-ubiquinone 
oxidoreductase and NADPH-cytochrome P450 metabolize menadione by one electron 
reduction, which subsequently undergoes redox cycling in the presence of oxygen to 
produce superoxide anion. However, other reductive enzymes including NADPH quinone 
oxidoreductase 1 (NQO1) metabolize menadione via a 2 electron reduction step, which 
creates a stable hydroquinone that is unable to enter redox cycling and generate ROS. 
NQO1 is thought to be a cellular detoxifying mechanism (Criddle et al., 2006), and 
therefore the oxidative stress induced by menadione may be quickly reversed via increased 
NQO1 expression. Criddle et al. (2007) reported the effect of menadione is highly 
dependent on NQO1 expression (Criddle et al., 2007). Further, increased NQO1 expression 
is observed during cellular differentiation alone indicating the abundance of this enzyme 
present during this process and therefore negating the effect of any quinones present (Zhao 
et al., 2009).  
Administration of NAC decreased DMSO-induced neutrophilic differentiation as 
measured by fMLP induced ROS production (Figure 13A, B). Further, NAC is able to 
inhibit both adipocyte differentiation of mouse embryonic fibroblasts and macrophagic 
differentiation of HL-60, via downregulation of ERK and JNK phosphorylation (Chien et 
al., 2013; Pieralisi et al., 2016). Similarly, inhibition of ROS production decreases 
monocytic differentiation into macrophages through the ERK pathway (Zhang et al., 2013). 
Interestingly, Chen et al. (2012) report that ROS produced from NADPH oxidase during 
HL-60 cell differentiation are essential for this process (Chen et al., 2012). Moreover, 
inhibition with antioxidants is able to inhibit the final differentiated phenotype, while the 
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opposite is also true. Specifically, the differentiation of promyelocytic leukemia cells 
(NB4) is enhanced when superoxide dismutase is inhibited with siRNA while 
differentiation is inhibited through endogenous ROS quenching with antioxidant, NAC 
(Yang et al. 2015). Perhaps then, only endogenous levels of ROS production are required 
for differentiation and exogenous chemical inducers of ROS are redundant. This may 
explain menadiones inability to significantly increase levels of differentiation alone (Figure 
13A). 
4.1.3 Inhibition of DNA methyltransferases induced a similar 
galectin expression pattern to that produced by oxidative 
stress and neutrophilic differentiation. 
DNA methylation was investigated as a regulatory mechanism of galectin expression 
considering inhibition of DNA methyltransferases is associated with increased 
differentiation in leukemic cell lines (Qin et al., 2007). My results indicate increased 
differentiation following DNA hypomethylation with decitabine considering the marked 
significant increase in differentiation marker, p47phox (Figure 14A, B). Interestingly, the 
expression profile of HL-60 cells in response to decitabine (Figure 15) is similar to 
expression profiles induced by oxidative stress and neutrophilic cellular differentiation. 
Specifically, treatment with decitabine increased expression of galectin-1, -3 and -10 at 
both the transcript and protein levels (Figure 15). This suggests that promoter 
demethylation is, in part, responsible for regulating LGALS1, LGALS3 and LGALS10 levels 
during the oxidative stress response and HL-60 cell differentiation. Epigenetic changes 
including promoter hypermethylation are early events in neoplastic processes and 
contribute by silencing tumour suppressor genes (Jones and Baylin, 2002). In fact, 
methylated genes have been evaluated as biomarkers for detection of cancer (Fackler et al., 
2004). In particular, hypermethylation of the LGALS3 promoter has been validated as a 
marker for early diagnosis of prostate (Ahmed et al., 2009), and thyroid cancers (Keller et 
al., 2013). Similarly, the LGALS1 promoter is hypermethylated in colorectal 
adenocarcinoma cells and re-expression of this gene induces apoptosis (Satelli and Rao, 
2011). My study provides the first evidence of LGALS10 promoter methylation and its 
marked expression change over other galectins following decitabine treatment (Figure 
15A). Additionally, my study provides evidence for galectin-10 as a marker for oxidative 
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stress and cellular differentiation in the context of AML. Although no DNA methylation 
regulatory mechanism has been reported to transcriptionally regulate LGALS10, the 
promoter region shares many sequence similarities to that of LGALS1 and LGALS3, 
specifically, Sp1 binding sites (Dyer and Rosenberg, 2001). Interestingly, the transcription 
factor Sp1 has been reported to bind promoter regions sensitive to methylation and 
therefore protect genes from transcription repression (Höller et al., 1988). The decrease in 
LGALS9 gene expression following DNA demethylation (Figure 15A) indicates the 
potential for this galectin to be regulated by transcription factors that are repressed via 
methylation. Most interesting, the increase in LGALS12 expression following treatment 
with decitabine (Figure 15A) is not associated with the decrease observed following 
neutrophilic differentiation. Xue et al. (2016) report an inhibitory function for galectin-12 
during neutrophilic differentiation suggesting multiple and complex regulatory 
mechanisms for this galectin (Xue et al., 2016). 
4.1.4 JNK signaling is impacted by oxidative stress and 
differentiation and induces galectin expression. 
Perhaps most interesting is the contrasting regulatory effect of JNK signaling observed 
during oxidative stress and neutrophilic differentiation. Increased phosphorylated JNK 
levels were observed during oxidative stress while the opposite effect was seen during 
differentiation (Figure 16C, D). Further, the addition of NAC with menadione was able to 
rescue basal protein levels while the addition of NAC with DMSO had no effect (Figure 
16D). This indicates that JNK signaling during neutrophilic differentiation is not redox-
sensitive and that the LGALS3 and LGALS10 expression attenuated with the addition of 
NAC (Figure 9) may be done through other redox-sensitive MAPK pathways, i.e. p38 and 
ERK signaling. This effect may explain the differences in the galectin expression profiles 
of both processes. Differential phosphorylation of JNK in HL-60 cells is most likely 
dependent on the stimulus used and the incubation time, following treatment. For example, 
Wang and Studzinski (2001) showed that 96 hr DMSO-induced differentiation of HL-60 
is accompanied by a decrease in phosphorylated JNK levels while the inhibition of the p38 
MAPK pathway increases levels of phosphorylated JNK but only in response to 1,23 D3-
induced monocytic differentiation (and not neutrophilic). Further, TPA-induced 
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differentiation of HL-60 shows only a transient (~1 hr) increase in phosphorylated JNK 
before returning to control levels while still showing prominent levels of phosphorylated 
ERK (Chien et al., 2013). In fact, most studies show – through the use of JNK inhibitor 
SP600125 – that increased signaling through this pathway is not involved in HL-60 
differentiation (Chung et al., 2005; Yu et al., 2008). Therefore, it is probable that 
differential JNK levels during differentiation is a result of the inhibition or augmentation 
of other MAPK pathways. Increased phosphorylated JNK during oxidative stress, 
however, has been reported in a number of other studies (Kaneto et al., 2004; Wang et al., 
2008). Interestingly, JNK signaling has been reported as a protective mechanism against 
oxidative stress by inducing expression of protective genes (Wang et al., 2003; Wu et al., 
2009). Therefore, this may explain the observed downregulation of JNK signaling 
following neutrophilic differentiation – these genes are not necessary considering oxidative 
stress is needed in the promotion of differentiation. Additionally, this also helps explain 
the associated induction of apoptosis during differentiation. These results provide more 
evidence of the importance of JNK signaling during neutrophilic differentiation and insight 
into the treatment of AML differentiation through MAPK pathways associated with 
galectin expression.  
Both an inhibitor (SP600125), and activator (anisomycin) were used to investigate the role 
of direct JNK signaling on galectin expression (Figure 16A, B). Inhibition of JNK signaling 
led to decreased galectin expression while augmentation of this pathway increased galectin 
expression. Increased LGALS1 expression may be a result of an indirect (off/non-target) 
effect caused by inhibition of the JNK signaling pathway. For example, inhibition of 
specific MAPK pathways can drastically increase the expression of others (Wang and 
Studzinski, 2001). Specifically, inhibition of the p38 MAPK pathway potentiated the JNK 
pathway leading to activation of transcription factors implicated in HL-60 differentiation 
(Wang and Studzinski, 2001). Many MAPK pathways crosstalk with each other and often 
affect the same set of target genes. Therefore LGALS1 may be indirectly regulated through 
either ERK or p38 signaling as a compensatory response (Shen et al., 2003). A similar 
effect of decreased LGALS9 expression has been reported following inhibition of JNK 
signaling with SP600125 (Steelman et al., 2013); however, a subsequent decrease 
following exposure to anisomycin has not been investigated. Activation of LGALS10 has 
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been reported being reliant on AP-1 and Oct1 transcription factors binding to the GC box 
(Dyer and Rosenberg, 2001). AP-1 is heavily regulated through MAPK signaling pathways 
indicating the reported downregulation of LGALS10 is likely through decreased JNK 
signaling (Karin, 1995). The increase in LGALS12 expression following treatment with 
SP600125 (Figure 16A) is interesting considering its downregulation following 
neutrophilic differentiation, which is accompanied by decreased phosphorylated JNK 
levels. Thus, in the context of cellular differentiation LGALS12 is regulated through various 
networks besides JNK signaling. These data indicate the potential for off-target effects on 
galectin expression following regulation of JNK and the specificity for JNK signaling on 
only certain galectins. 
4.1.5 Galectin gene expression correlates with oxidative stress and 
differentiation. 
The correlation analysis indicates that there is both a strong positive and negative 
correlation of galectins with oxidative stress. Correlations between galectins with ho-1 and 
p47phox are indicative of galectins participating in both oxidative stress responses and 
differentiation, respectively. In particular, LGALS1, LGALS3 and LGALS8 were positively 
correlated with oxidative stress marker ho-1 (Figure 17A, B, C) whereas LGALS3, LGALS9 
and LGALS10 positively correlated with cellular differentiation marker p47phox (Figure 
18B, D, E). These findings suggest galectins as biomarkers of oxidative stress in the context 
of leukemia. Both LGALS1 and LGALS3 have been proposed as biomarkers of other 
cancers such as renal cell carcinoma – a malignant tumour typically associated with levels 
of oxidative stress (Ganesamoni et al., 2012; von Klot et al., 2014). More generally, 
galectin-3 has been proposed as a marker of fibrosis, which is a process highly associated 
with oxidative stress in the context of cardiovascular diseases (Hrynchyshyn et al., 2013). 
Additionally, LGALS12 negatively correlated with both ho-1 and p47phox (Figure 17F and 
Figure 18F). Decreased LGALS12 transcript levels is suggested as an additional biomarker 
of cellular stress responses. Decreased LGALS12 transcript levels during neutrophilic 
differentiation may be due to this proteins effect on cell cycling (Yang et al., 2001), as it 
has been shown that LGALS12 can inhibit human NB4 promyelocytic leukemia cell 
differentiation (Xue et al., 2016). Interestingly, LGALS10 only positively correlated with 
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p47phox (Figure 18E) while showing no correlation with ho-1 (Figure 17E) indicating the 
expression of this galectin is specific for neutrophilic differentiation and its function is 
potentially unrelated to its oxidative stress sensitivity. Additionally, galectin-10 has been 
proposed as a potential biomarker for eosinophilic airway inflammation based on its 
correlation with sputum eosinophil levels (Chua et al., 2012). My findings suggest that 
galectin-10 transcript levels may be a ubiquitous marker for other granulocytes in the 
context of differentiation. LGALS8 expression did not correlate with differentiation marker 
p47phox (Figure 18C). This is interesting considering LGALS8 overexpression has been 
shown to enhance osteoclast differentiation (Vinik et al., 2015), and T-cell differentiation 
(Sampson et al., 2016). Potentially, LGALS8 role in differentiation is cell type/context 
specific. These findings provide insight to expression patterns of galectins in a leukemic 
model under oxidative stress and DMSO-induced differentiation. 
In order to further analyze galectin expression patterns; correlations between galectin 
isoform expressions were performed to determine potential galectin redundancy. 
Generally, galectin-8 expression across treatments remained invariable; however, there 
was a significant positive correlation between LGALS1 and LGALS8 indicating the 
potential for redundancy between these proteins (Figure 19B). Other studies have shown 
functional redundancy between galectin-1 and galectin-8 when promoting plasma cell 
differentiation (Tsai et al., 2011), and eliciting T-cell responses (Tribulatti et al., 2012). My 
results also indicate a significant positive correlation between LGALS1 and LGALS3 
transcript levels (Figure 19A). There is a precedent for correlated expression between 
LGALS1 and LGALS3 in cancer lines (Wang et al., 2000), however, the function of these 
two proteins is likely related to their cellular localization/distribution rather than their 
correlation being functionally redundant (Sanjuán et al., 1997). The significant negative 
correlation between LGALS8 and LGALS9 transcript levels (Figure 19H) is interesting 
considering these two proteins have been shown to exist as multiple splice variants (Nishi 
et al., 2006). These variants contain structural similarities allowing these proteins to be 
affected by other molecular factors in similar fashion. For example, isoforms of galectin-8 
and galectin-9 containing the longest linker peptide regions are more susceptible to 
cleavage (Nishi et al., 2006). The correlation existing between transcript levels of these 
two galectins is likely due to structural features as a consequence of alternative splicing. 
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Future studies should identify expression patterns of individual splicing transcript variants 
to confirm my findings or determine new correlations. Interestingly, there was a correlation 
with LGALS10 and LGALS12 transcript levels (Figure 19K) indicating the potential for 
similar expression patterns and redundancy. No transcript level correlation between these 
galectins has been investigated; therefore, future studies should aim to identify similar 
expression patterns across other treatments to identify new correlations considering both 
galectins are involved within differentiation. 
The positive correlation between ho-1 and p47phox transcript levels (Figure 20) indicates 
a strong association between oxidative stress and neutrophilic differentiation considering 
many galectins correlate with both markers; galectins may be considered biomarkers and 
potentially mediators of these two processes. In particular, the link between oxidative stress 
and its contribution in promoting differentiation is, in part, through upregulation of 
galectins. Although JNK signaling is differentially affected by differentiation and oxidative 
stress; galectin expression remains variable indicating not only are galectins biomarkers 
for both processes, but galectins may also feedback to promote the differentiation of 
promyelocytes in HL-60 cells. 
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Figure 21. Suggested pathway of menadione-induced oxidative stress and DMSO-
induced neutrophilic differentiation of HL-60 cells. 
The above schematic is the proposed method for galectin contribution in DMSO-induced 
HL-60 neutrophilic differentiation (Figure 21). It is speculative that JNK signaling works 
to increase Sp1 nuclear translocation and activation to increase galectin expression 
responsible in promoting cellular differentiation. Additionally, galectin expression by other 
MAPK pathways following DMSO treatment is also speculative. However, my study 
indicates that increased galectin gene expression following JNK activation, oxidative 
stress, and inhibition of DNA methyltransferases, is prominent. ROS signaling must 
precede differentiation considering treatment with NAC was able to successfully inhibit 
differentiation in all cases. Future studies should include in-depth individual galectin 
analyses to identify specific differences between galectins, helping to eliminate the 
assumption of functional redundancy. 
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4.2 Conclusions and application 
In conclusion, I have determined the galectin expression profile of HL-60 cells under 
oxidative stress and during DMSO-induced neutrophilic differentiation. Similarities in 
galectin expression including upregulating of galectin-1, -3 and -10 at either the transcript 
or protein levels indicates an association between cellular differentiation and the redox 
environment with respect to galectins. The differential expression of galectins following 
oxidant exposure suggests these proteins may represent markers of the cellular stress 
response. It also suggests the potential for galectin-1, -3 and -10 as clinical targets when 
developing therapeutic treatment for AML. 
Using different galectin inhibitors, galectin-1 is, at least, suggested to play a role in cellular 
proliferation and the progression of HL-60 cell differentiation. Considering other galectin 
inhibitory sugars (besides TDG) displayed no effect on either process, it is likely that these 
galectins either are not significantly involved, or are working in a CRD-independent 
fashion intracellularly to facilitate their biological role. Additionally, the upregulation of 
galectin-1, -3 and -10 following DMSO-induced expression may be an indirect effect of 
differentiation, including: apoptosis or cell cycle arrest. These data suggest the complex 
role of galectins in HL-60 cell stress response and differentiation despite their widespread 
expression and often structural redundancy. 
Investigation of the redox environment was accomplished using the oxidant menadione 
and antioxidant NAC. My results suggest the addition of NAC is sufficient to reduce the 
levels of DMSO-induced neutrophilic differentiation of HL-60 cells while menadione was 
unable to enhance this effect. Understanding the role of ROS during differentiation is 
important considering the crucial roles of free radicals in the pathogenesis of many diseases 
(e.g. cancer due to loss of differentiation) (Ye et al., 2015). Further, considering galectins 
are involved with many types of cellular differentiation, the regulatory mechanisms 
associating ROS and cellular differentiation may be, in part, mediated through galectin 
expression. For example, ROS production has been known to facilitate adipocyte 
differentiation, which also requires galectin-12 expression (Lee et al., 2009; Yang et al., 
2004). These results suggest an association between oxidative stress and cellular 
differentiation with respect to both up and down regulation of galectins. Finally, these data 
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suggest galectins may act as major players in the pathogenesis of diseases attributed to 
ROS production. 
JNK signaling and DNA methylation are two distinct regulatory methods of galectin 
expression during oxidative stress and differentiation. The galectin expression profile 
generated from demethylation shows similarities to that of oxidative stress and DMSO-
induced neutrophilic differentiation including upregulation of galectins-1, -3 and -10. 
Therefore, it is possible that other epigenetic mechanisms are involved with these two 
processes with respect to galectin expression. Interestingly, neutrophilic differentiation and 
oxidative stress produced distinctly opposite expression patterns with decreased 
phosphorylated JNK levels following differentiation and increased levels following the 
addition of menadione. This suggests the potential for different MAPK pathways or other 
regulatory mechanisms to be involved with galectin expression during these two processes 
despite the similarities in expression. 
The correlation analysis revealed coordinated galectin expression as a potential biomarker 
for oxidative stress and differentiation of HL-60 cells. Specifically, LGALS1, LGALS3 and 
LGALS8 may be considered biomarkers of oxidative stress while LGALS3, LGALS9 and 
LGALS10 may be considered biomarkers for HL-60 neutrophilic differentiation. 
Downregulation of LGALS12 may be considered a negatively correlated biomarker for both 
oxidative stress and neutrophilic differentiation. Correlation between marker genes of each 
process suggests that galectins act as mediators responsible in promoting differentiation 
following oxidative stress. Finally, correlated expression amongst different galectin 
indicate the potential for functional redundancy; however, further analysis of individual 
galectins is required to draw specific and definite conclusions. 
In conclusion, this study demonstrates an association between oxidative stress and 
neutrophilic differentiation of HL-60 cells with respect to upregulation of galectins. 
Distinct similarities and differences in galectin expression profiles provide insight to 
different regulatory mechanisms associated with these processes and the potential for 
galectin expression as biomarkers of different biological processes and stress responses. In 
particular, galectins and their expression associated with AML and differentiation may be 
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considered a clinical target when developing various drug treatments/therapeutic 
medication. 
4.3 Study limitations and future directions 
One major project limitation was the inability for genetic manipulation: specifically 
knockdown experiments utilizing RNAi based techniques. Like many leukemic cell lines, 
HL-60 cells have been reported as being transfection-incompetent in comparison to other 
lines such as K562 (Esendagli et al., 2009). Despite this, more sophisticated methods of 
gene delivery such as lentiviral techniques have proven useful for RNAi in the context of 
studying HL-60 cellular differentiation (Jian et al., 2011). More recent techniques 
including the powerful gene editing tool CRISPR/Cas9 system has proven useful for 
manipulating gene expression for studying myeloid leukemia in the context of 
differentiation (Valletta et al., 2015). Specifically, CRISPR/Cas9 directed gene knockdown 
is very specific and eliminates indirect/off-target effects that may be associated with the 
galectin inhibitors used in this study. In this way, I could study the effect inhibiting 
galectins that are typically upregulated during differentiation and then test for the 
neutrophilic phenotype. 
Another method to examine the effect of individual galectins on cellular proliferation other 
than genetic manipulation using RNAi would be to utilize glycan modification enzymes/ 
drugs to alter glycan structure, i.e. remove terminal sialic acid glycan residues. Different 
galectins, for example, have shown similar specificity toward LacNac binding; however, 
the addition/removal of 2–3-sialic acid on terminal LacNac structures can significantly 
change specificity of only specific galectins (Stowell et al., 2008). This method allows for 
analyses of only endogenously expressed galectins. Exogenously added recombinant 
galectins are often used to assess the role of individual galectins on cellular functions when 
added in abundance. 
Another study limitation is the use of DMSO as a “specific” inducer of neutrophilic 
differentiation. DMSO was originally described to induce neutrophilic differentiation 
based on morphological changes (Collins et al., 1979). It has been reported that HL-60 
cells induced with DMSO can undergo defective neutrophil maturation evident by failure 
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of secondary granule gene expression; therefore, these cells may only represent an atypical 
phenotype of proper granulocytes (Khanna-Gupta et al., 1994). In fact, DMSO-induced 
differentiation increases CD14 expression: a common marker of monocytic differentiation 
into mature macrophages (Zamani et al., 2013). Therefore, future studies should include – 
in addition to multiple promyelocytic cell lines – multiple neutrophilic differentiation 
stimuli such as all-trans retinoic acid (ATRA) when comparing galectin expression 
profiles. This is especially important considering lineage specific differentiation using 
various chemical inducers enables different galectin expression profiles (Abedin et al., 
2003). Additionally, investigation of specific transcription factors affected by JNK 
signaling should be investigated. In particular, chromatin immunoprecipitation analyses 
could be utilized to identify specific interactions between galectin DNA sequences and 
relevant transcription factors such as Sp1. Considering expression of specific galectins are 
changed during oxidative stress and differentiation, identification of transcription factors 
responsible for this increase would offer insight to potentially many signaling pathways. 
Another study barrier was the limitation of immortalized cell lines. Animal models would 
provide a more physiologically relevant system in order to identify the specific roles of 
galectins. The inclusion of primary cultures may also offer a better model for examination 
of galectins. Further studies using these more physiological models to confirm the findings 
presented here would be the next step to further validate galectins as key regulators of 
neutrophilic differentiation and possible regulators of leukemic progression. 
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Appendix A: supplementary material 
 
Gene Name 
& RefSeq 
 
Sequence, 5’ – 3’ 
 
Size 2 Step Cycling (RT-qPCR) 
3 Step Cycling (RT-PCR) 
PCR 
efficiencies & 
quantification 
method 
PMCID or 
PMID for 
reference 
(if 
applicable) 
LGALS1 
NM_002305 
F CCTGGAGAGTGCCTTCGAGTG 
220bp 
Denaturation: 95°C for 5 Sec 
Anneal/Extend: 60°C for 25 Sec 
100% 
23108139 
R CTGCAACACTTCCAGGCTGG ∆∆Ct 
LGALS3 
NM_002306 
F CAGAATTGCTTTAGATTTCCAA 
108bp 
Denaturation: 95°C for 5 Sec 
Anneal/Extend: 60°C for 25 Sec 
113% 
18202194 
R TTATCCAGCTTTGTATTGCAA Pfaffl 
LGALS8 
NM_006499 
F TGGGGACGGGAAGAGATCAC 
172bp 
Denaturation: 95°C for 5 Sec 
Anneal/Extend: 62°C for 25 Sec 
81.4% 
Designed 
R TGCCATAAATGCCCAGAGTGTC Pfaffl 
LGALS9 
NM_009587 
F CTTTCATCACCACCATTCTG 
91bp 
Denaturation: 95°C for 5 Sec 
Anneal/Extend: 62°C for 25 Sec 
86.8% 
18202194 
R ATGTGGAACCTCTGAGCACTG Pfaffl 
LGALS10 
NM_001828 
F GGATGGCCAAGAATTTGAACTG 
82bp 
Denaturation: 95°C for 5 Sec 
Anneal/Extend: 62°C for 25 Sec 
112.6% 
Designed 
R GGTGTAAGAGGATTGGCCATTG Pfaffl 
LGALS12 
NM_001142
535 
F TGTGAGCCTGAGGGACCA 
111bp 
Denaturation: 95°C for 5 Sec 
Anneal/Extend: 65°C for 25 Sec 
83.6% 
18202194 
R GCTGAGATCAGTTTCTTCTGC Pfaffl 
p47phox 
NM_000265 
F GTCAGATGAAAGCAAAGCGA 
93bp 
Denaturation: 95°C for 5 Sec 
Anneal/Extend: 60°C for 25 Sec 
OR 
Extend: 72°C for 60 Sec 
ND* 
23147401 
R CATAGTTGGGCTCAGGGTCT ∆∆Ct 
ho-1 
NM_002133 
F CTCAAACCTCCAAAAGCC 
220bp 
Denaturation: 95°C for 30 Sec 
Anneal/Extend: 60°C for 30 Sec 
OR 
Extend: 72°C for 60 Sec 
- 
PMCID: PM
C2175339 
R TCAAAAACCACCCCAACCC - 
GAPDH 
NM_002046 
F GAGTCAACGGATTTGGTCGT 
95bp 
Denaturation: 95°C for 5 Sec 
Anneal/Extend: 62°C for 25 Sec 
93.3% 
PMCID: PM
C3489664 
R AATGAAGGGGTCATTGATGG Pfaffl 
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Table 1. Primer sequences and RedSeq, amplicon size, cycling conditions, 
efficiencies, method of quantification and primer references. 
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slope <- function (data,n){  
  j.max <- n-1 
  b1 <- list() 
  max <- length(data$V1) - n + 1 
  for (i in 1:max){ 
    d.max <- n+i-1 
    sub.data <- data[i:d.max,] 
    b <- list() 
    m <- 0 
    for (j in 1:j.max){ 
      k.min <- j+1 
      for (k in k.min:n){ 
        m <- m + 1 
        b[m] <- (sub.data[j,2] - sub.data[k,2]) / (sub.data[j,1] - sub.data[k,1]) 
} 
} 
    b1[i] <- median(unlist(b)) 
} 
  b1 
  x <- which.min(unlist(b1)) 
  r1 <- data[x + round(n/2),1] 
  r2 <- data[x + round(n/2),2]  
  r3 <- b1[x] 
  result <- cbind(r1, r2, r3) 
} 
 
Algorithm 1. (A) R code used to determine the minimum first derivative of the negative 
slope indicative of the time point at which the slope is steepest. Algorithm describes a 
moving window of 10 units (seconds) from initial time of reading (0 seconds) to 900 
seconds. (B) Example kinetic from fluorometric assay. Illustration shows the moving 
window used to determine the steepest point of the slope. 
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